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Editorial 
Climatic governance 
and political warming 
Apparently, the 'Earth Summit' in Johannesburg 
will prove to be no exception to the rule which 
seems to apply to most events of this type, leaving 
in its wake a sense of disappointment mixed with a 
degree of satisfaction. While the absence of resolu­
tions setting concrete and quantifiable objectives 
was widely condemned ­ especially by non­gov­
ernmental organisations ­ this global meeting did 
produce two positive results. 
First, there are the priority themes which finally 
dominated the Summit conclusions: water, health 
and poverty. Clearly identifying these three basic 
concerns to humanity as fundamental objectives is 
encouraging and shows that such major meetings 
are not totally removed from reality. 
Secondly, there is the image of mobilisation and 
solidarity presented by the European Union. This 
certainly played a part in achieving most of the 
objectives the Commission had set itself. 
At the same time, a note of disappointment must 
be sounded regarding the relative sidelining of 
science. The scientists may have been heard but 
they were not really listened to. Some of the politi­
cal speeches ignored or even contradicted the 
'facts' now supported by an accumulating mass of 
evidence. Hence the importance of good gover­
nance. It is simply not enough to support research 
financially; its results must also be communicated, 
discussed, shared and taken into account. Money 
alone is insufficient. There is a price to be paid for 
benefit ing fully from the finance allocated to 
research and development. 
We must recognise that the general context today 
is not the most favourable. Humanity is in great 
need of climatic governance and of a political 
warming to the cause. 
DOSSIER 
3 The revolution revs up 
4 The crazy decade 
of sequencing 
Yeast, the Bacillus subtilis bacteria, 
the Arabidopsis thaliona plant, mice... 
and then man ­ the sequencing adventure 
is only just beginning and the life sciences 
are entering the age of genomics. 
Β The age of the 
researcher­entrepreneur 
The 'cultural revolution' of the scientist 
business manager. 
Marine biodiversity 
niThe lilliputians 
of the plankton world 
In the ocean depths, miniscule micro­
organisms play a vital role in the world's 
major ecosystems. 
Sustainable development 
Π1 Revealing the hidden 
costs of energy 
'Externalities' count the cost of 
the 'collateral' requirements, particularly 
in the field of health and the environment, 
which must be taken into account when 
calculating the price per kWh. 
Space applications 
10n Earth as in the Heavens 
Specialised incubators are networking 
to enable innovative SMEs to 'translate' 
the advances in space research into 
high­tech applications in other fields. 
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7 Investors in the long term 
The increase in venture capital and the 
development of new stock markets are 
bringing interesting new opportunities for 
Europe's young high­tech companies. 
β A wealth of start­ups 
Record growth for biotechnology. 
π Decision time for 
the Union 
The Life sciences and biotechnology 
action plan. 
Coal and steel research 
E l Far from finished 
Post ECSC 
E l The quest for clean coal 
Research on the clean burning of coal ­
a safe energy source in abundant supply 
­ is a key element in European strategy. 
Steel has a tough life 
As producer of 20% of the world's steel, 
the EU is market leader. 
A marriage of increased 
productivity and 
environmental 
improvements 
A durable and recyclable material, 
steel has reduced Its CO2 emissions 
by 50% as researchers pursue the 'zero 
waste' target. 
Portrait 
The beauty of theory 
A conversation with Gerard 't Hooft, 
1999 winner of the Nobel Prize in Physics. 
Poverty­related diseases 
E l Aids, malaria, tubercu­
losis: an urgent clinical 
counter­attack in Africa 
Poverty engenders disease which in turn 
generates further poverty. The fight 
against the spiral of distress afflicting 
sub­Saharan Africa includes an urgent 
need for clinical research. 
Women and science 
f u Equal skills for an equal 
career? 
About 30 countries came under the 
microscope when the Helsinki Group 
studied policies, good practices and 
statistics on the gender balance. 
Recent publications 
I Introduction to the Sixth 
Framework Programme 
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The revolution 
'Take increased investments, evolution in the legal 
framework and a new culture, and you have a 
so-called Old World able to compete with the 
United States.' It was in these terms that in May 
this year the American Time magazine painted a 
decidedly optimistic picture of the biotechnology 
sector in Europe. Although the United States has 
experienced an unrivalled boom in this field over 
the past decade, today there are unmistakable signs 
of a European awakening - among policy-makers, 
researchers and investors - based on the dynamics 
of rapprochement between the fundamental life 
sciences and their applications. 
An inseparable pairing of science and technology, a series of 
discoveries and a spirit of innovation have resulted in the 
biotechnologies providing a constant source of new applica-
tions in the fields of health, agriculture and the environment. 
They are enabling several traditional industrial sectors to regen-
erate and, more spectacularly, they are spawning new and 
innovative companies which already employ 87 000 people in 
the European Union. As stressed by European leaders at the 
Lisbon (2000) and Stockholm (2001) summits, as a result of 
their commitment to the acquisition of new knowledge, 
biotechnology companies are a vital element in Europe's acces-
sion to a knowledge-based economy. 
This is a sector which reveals the true value of the European 
Research Area. 'European biotechnology can only compete with 
the rest of the world if we maximise research co-operation and 
minimise useless duplication. High-level researchers, whether 
working in the private, public or academic sector, must be the 
first to benefit from this quest for synergy,' stressed Philippe 
Busquin, European Commissioner for Research, at the major 
Biovision Forum held in Lyons (France) in February 2001. But the 
battle is not being fought in the scientific field alone. There is 
also a need to create an economic environment which encour-
ages the creation of innovative companies or 'DNA start-ups', as 
they are sometimes called, which have doubled in number in 
Europe over the past five years. 
The stakes are high with a European biotechnology market 
expected to be worth over €100 billion by 2005. Encouraging 
and training researcher-entrepreneurs, granting them access to 
financial resources through more open and abundant venture 
capital, and providing Europe with more coherent regulations 
on the marketing of biotechnological products are the main 
lines of the new strategy which the Commission - after wide-
revs u 
NeuroSearch 
ranging consultation with scientists, economists and politicians 
- has proposed to the Member States and European Parliament 
(see Decision time for the Union). 
In forging ahead in this way the greatest attention must also be 
paid to the heated public debate about this ongoing 'revolu-
tion'. How can progress in the life sciences be reconciled with 
the concerns of society? EU countries and the Commission have 
already taken initiatives to this effect, such as their commitment 
to giving clear priority to consumer protection and to consider-
ing the interests of the most vulnerable groups. New ethical 
questions have also caused the Commission to prohibit any 
funding of research on human reproductive cloning. These 
measures must be further strengthened as 'commitment to fun-
damental ethical values will be crucial in creating confidence 
and winning public support for the new biotechnologies', as Com-
mission President Romano Prodi stated at the Lisbon Summit. O 
RTD i n f o N'J 35 October 2 0 0 2 O T E C H N O L O G Y Ι N E U R O P E 
Arabidopsis 
thaliana, 
the first plant 
to have its 
genome 
decoded, 
in 2001. Here, 
a collection of 
strains which 
have been 
generated 
at the plant 
improvement 
greenhouses 
at Versailles 
(France). 
© |ean Weber 
The announcement, in June 2000, that the human genome had been sequenced was a global event. 
It is symbolic of the life sciences entering the age of genomics and brings with it the promise of many 
new applications. 
The crazy decade 
of sequencing 
Over the past decade, biology has experienced one of the 
most radical transformations in its history: the decoding of 
genomes. Scientists had known since the 1950s that the 
genetic inheritance of all living creatures was desoxyribonucleique 
acide (DNA), a giant molecule in the form of a double helix, 
which is the main constituent of chromosomes. DNA carries 
the information needed for the synthesis of all proteins, which 
are the chemical building blocks of living creatures. Even 
when molecular biology was still in its infancy, biologists knew 
that each protein was coded by a gene: a long sequence of 
four chemical letters - the nucleotide sequence - which is the 
basic structural unit of DNA. 
It remained a huge task, however, to decipher a text written 
in such a 'rudimentary' alphabet. It took the British scientist 
Frederic Sanger several years before he finally managed to 
decode the several thousand nucleotides which make up the 
genome of a small bacterial virus. Sequencing the human 
genome, with its 3 billion 'nucleotide letters', was a daunting 
prospect. 
From genetics to genomics 
Yet it was this sequence, decoded almost in full, which was 
published in 2000 by a world-wide consortium of laboratories, 
including the Sanger Centre in the United Kingdom which 
alone carried out one-third of the work. This remarkable inter­
national effort was the climax of the genome race in which 
Europe had been a forerunner. European research groups, 
supported by the Commission, had decoded the first genome 
of a nucleic cell (yeast) in 1997, followed by the bacteria Bacillus 
subtilis, which is very important in agri-foodstuffs, and finally, 
in 2000, the first plant, Arabidopsis thaliana. Today, the 
genomes of several dozen micro-organisms, including some 
model species for biologists, such as the Coenorhabditis 
elegans worm, the fruit fly (drosphila), the mouse - and, of 
course, man - have all been sequenced. 
But the adventure is only just beginning. 'A concerted effort is 
now needed to exploit this vast medical, social and economic 
potential,' stressed Philippe Busquin in response to the 
announcement that the human genome had been successfully 
sequenced. Indeed, decoding the chain of nucleotides in a 
sequence is really only the beginning. The next steps are to 
seek potential genes, understand the variability between one 
individual and another, and to identify the mutations respon­
sible for specific characteristics. 
It is at this point that genetics gives way to genomics, or the 
study of the coordinated expression of the complete genome 
rather than just an isolated gene. Genomics - and its close 
relative proteomics which is concerned with the study of all 
the proteins in a living organism - are inextricably involved in 
the computer processing of sequences by DNA chips. The latter 
permit the automatic sequencing of nucleotide chains. 
Key role for bio-informatics 
To develop this booming discipline, the European Commission 
granted €9.4 million to the new European Bio-Informatics 
Institute in the United Kingdom, an offshoot of the prestigious 
European Molecular Biology Laboratory (EMBL) in Heidelberg 
(DE). The EMBL was at the origin of the E-Biosci project (which 
also received Commission funding, to the sum of €2.4 million) 
to create a huge databank of information and publications on 
genomics, to which there is free access. 
This expansion of bio-informatics clearly illustrates one of the 
central characteristics of biotechnologies: their interdiscipli-
narity. The pioneers of genome studies were physicists. 
Chemists then took over to decode the genetic code, and now 
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it is the turn of the computer scientists. 'Biotechnology would 
not assume such importance without the contribution of 
other sciences and technologies. Molecular biology would be 
unable to play a significant role in the global economy without 
chemistry, biochemistry, physics, electronics and informatics. 
Also, industrial and economic development necessarily 
involves human resources management, commercial law, 
intellectual property rights and finance,' explains Daniel 
Dupret, head of the Proteus company and an expert with the 
Research Directorate-General. 
A thousand and one genome 
applications 
Biotechnologies thus constitute a knowledge, tools and tech-
nology base with applications in a range of sectors, such as 
pharmacy, agri-foodstuffs, chemistry and environmental pro-
tection. The medicines production industry has already had 
recourse to technologies originating in the knowledge of 
genomes, for example. Insulin, obtained previously from pig 
livers, is now produced in bioreactors by bacteria or yeasts 
whose genetic make-up has been modified to add the coding 
gene for human insulin. This type of process, which makes it 
easier to satisfy quantitative requirements while at the same 
time providing a better guarantee of quality and safety, will 
soon be perfected for plants too which will then be able to 
produce therapeutic proteins under conditions of complete 
health safety. Over the next few years, progress in the life 
sciences will no longer give rise to new processes but rather to 
entirely new products. 
Coal, oil, and then silicon 
(with the arrival of electronics 
in the 1970s) each triggered an 
industrial revolution. For historians, 
DNA will no doubt be seen 
as the material behind the revolution 
we are experiencing today. 
Above, DNA sequences revealed 
to decode the human genome. 
© INSERM: B.jordan/M.Hunapiller 
In the field of health, genomics promises not just to treat previ-
ously incurable genetic diseases but also to develop treatment 
adapted to individual patients depending on their specific 
genetic heritage (see box). In agriculture, mastering genomes 
and the genetic modification of plant characteristics will per-
mit a qualitative impact as well as an agronomic one. A good 
example of this is golden rice which is genetically modified to 
produce the beta-carotene molecule, a precursor of vitamin A 
that it does not contain naturally. Developed with EU support, 
this food could help fight blindness associated with a vitamin 
A deficiency which affects 200 million children worldwide 
every year. 
Finally, new services could also be developed, thanks to the 
extraordinary power of the DNA chip which is able analyse 
the expression of an entire genome. It will be possible, for 
example, to define a sick cell at the genetic level or to measure 
the toxicity of new chemical substances without recourse to 
animal experimentation. O 
The enigma of methylation 
The DNA sequence is a long chain of four chemical letters: the nucleotides. We know that these can exist in two forms: 
the traditional form and the so-called methylated form, which occurs when a certain hydrogen atom has been replaced by 
a methyl group (CEb). The methylation of nucleotides does not change the nature of the coded protein. Rather it controls 
the level of expression by acting as a kind of 'off/on' switch for genes. In particular, different levels of DNA methylation, 
transmitted through the hereditary process, are associated with certain cancers. 
The Human Epigenome Consortium, set up in 1999, aims to improve our understanding of the role of methylation in 
human diseases. The network, which the Commission supports as part of its 'infrastructure actions', includes the project 
co-ordinator Epigenomics of Germany as well as leading German sequencing centres (Berlin Technological University and 
the Max Planck Centre for Molecular Biology). 'Our principal objective is to construct a methylation map for the entire 
genome,' explains Alexander Olek of Epigenomics. (') This is expected to have repercussions for cancer treatment, which 
is why the German Centre for Cancer Research in Berlin is also a member of the Consortium. Knowledge of a tumour's 
methylation profile - its digital phenotype - would make it possible to tailor treatment more specifically to the cancer 
cell characteristics. 
To find out more 
Owww.nalure.com/Benomics/ 
(/) Alexander Olek 
was named 'best 
entrepreneur of 2001 ' 
in the start-up category 
by Ernst and Young. 
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The time when universities and businesses regarded 
each other wi th mutual suspicion is well and truly 
over. In recent years the symbolic figure of 
the researcher-entrepreneur has become central to 
the organisation of research. The age 
of the researcher-
entrepreneur 
Aware of the development 
of spin-offs and the desire 
of young researchers 
to give their work an 
entrepreneurial dimension, 
many European universities 
are now including 
a business creation 
component in their courses. 
© NeuroSearch 
To find out more 
OEurobiobiz 
www.curobiobiir.com 
OBiotechnology ami finance lorum 
http://curopa.eu.int/comm/ 
research/biotcch/finance.html 
'In the 1980s, most biologists who set up their own com-
panies were scientists w h o had achieved a certain 
renown. Today, most of these budding entrepreneurs are 
younger researchers who are unable to fall back on their 
name or their contacts but who already have specialist 
knowledge and are at t racted by the entrepreneur ia l 
adventure,' explains the Belgian researcher and specialist 
in immunology Donny Strasberg. As the co-founder of 
a number of b io techno logy companies over the past 
20 years, he was in at the beg inn ing of this 'cultural 
revolution' which has given birth to a new kind of start-up. 
Cultural change 
Before taking the plunge, however, one must first have 
the training. Traditional academic culture - based on the 
widest possible dissemination of results wi th in the inter-
national scientific communi ty - is very different to private 
research wh ich is guided pr imari ly by the quest for a 
competit ive edge. A researcher who plans to become an 
entrepreneur must therefore learn to keep things under 
wraps a little if he does not want to see his ideas stolen by 
his competitors, thereby robbing him of the rewards gen-
erated by their industrial application. He must also plan 
his company's activities over the years to come, raise 
investment capital, anticipate expenditure and revenue, 
draw up a business plan and enlist the help of genuine 
business managers. As European universities have grown 
increasingly aware of this trend - and of its benefits - so 
they have started to provide t ra in ing on the many 
aspects of setting up a company. 
For those w h o are already work ing and have l imi ted 
t ime, the Eurobiobiz company (which received € 1 9 3 000 
f r o m the Commiss ion in 2002 ) holds workshops for 
fu ture researcher-entrepreneurs on subjects inc luding 
account ing, intel lectual property, negot ia t ion, human 
resources managemen t and raising funds. These all 
feature in the programme dur ing the three-day training 
courses held nearly every month in a different European 
capital. Twenty-five European biotechnology companies 
have already been set up by graduates f rom these courses. 
Setting up a company is not, of course, the culminat ion 
of the efforts of the lone researcher-entrepreneur. It is the 
result of countless meetings, contacts and negotiations 
with financiers able to back what are often costly projects. 
This is why every year the 'Biotechnology and Finance', 
forums - initiated in 1998 by the Commission and the 
European Association of Security Dealers - br ing new 
biotechnology companies and researchers wi th interest-
ing ideas into contact w i t h representatives f r o m the 
wor ld of industry and finance who are in a position to 
help them raise the funds they need. 
Double flexibility 
Once a company reaches a certain stage in its develop-
ment, it becomes impossible for the researcher-entre-
preneur to run the business single-handed. At this point 
a specialist must be brought in to take control of business 
and financial management. Some of these become busi-
ness angels, stepping in when needed to make their expe-
rience available to young researcher-entrepreneurs, while 
others become serial business creators. As Donny Stras-
berg explains, 'When you notice you are becoming less 
useful in a company because the research has reached 
the development stage you then have to know how to 
step aside and make your skills available to another 
organisation.' O 
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Investors in 
the long term 
Research Is expensive. A young 
biotechnology company has to raise 
new capital at each stage of its 
development. The growth of venture 
capital in Europe and the development 
of new stock markets have facilitated 
access to this vital ingredient 
When studying the feasibil ity of a project to create a 
biotech company, private investment and national subsi-
dies are usually enough . But for the actual s tar t -up, 
recourse to venture capital funds is needed. These spe-
cialised f inancial structures invest simultaneously in a 
number of high-tech companies, count ing on the profits 
made by the fortunate few to offset the losses incurred by 
those who fail. 
Europe's helping hand 
For many years a lack of venture capital was a brake on 
the development of advanced technologies in Europe, 
especially in the life sciences. This was in marked contrast 
to the United States where this specialisation made its 
appearance back in the late 1970s. To correct the defi-
ciency, the Commission turned to the European Invest-
men t Bank (EIB), wh ich launched the ¡2i init iat ive, mak-
ing a bi l l ion euro available to venture capital operat ions 
over the fo l lowing 12 months, mainly in new information 
technologies and biotechs. The EIB also operates through 
the European Investment Fund (EIF) in wh ich it has a 
6 0 % stake (30% being held by the Commission and 1 0% 
by major financial institutions). The EIF helps high-tech 
companies to start up by f inancing business incubators, 
and it is biotechnology wh ich , in practice, benefits most 
f rom this mechanism. Most recently, the EIF has invested 
€ 2 0 mill ion in Heidelberg Innovation in Germany, € 2 9 
mil l ion in MVM International Life Science (a subsidiary of 
the British Medical Research Council) and a further €1 0.5 
mil l ion in Nordic Biotech K/S which incubates start-ups in 
the Scandinavian Medicon Valley. 
The end result is that European biotechnology companies 
are now able to count to a growing extent on experi-
enced venture capital funds wi th available capital. Conse-
quently, viable projects which fail to get off the ground 
are becoming increasingly rare. In fact, venture capitalists 
who, two or three years ago, preferred to invest in new 
informat ion and communicat ion technologies are now 
turning their attention to life science companies which 
they see as having better long-term prospects. At a t ime 
of stock market unrest, the latest figures cited in the Ernst 
& Young report conf i rm this. Whereas venture capital 
investments in the h igh technologies fell by 3 1 % 
between 2000 and 2001 - the bursting of the Internet 
bubble decimated the ICTs - investments in biotechnol-
ogy companies fell by just 1 6% compared w i th 2000, a 
year which had broken all records. The only cause for 
concern was the low investment in biotech projects for 
agriculture. Venture capitalists fear the consequences of 
the publ ic debate on GMOs and are reluctant to invest 
in agri-biotechs in Europe at a t ime when the sector is 
booming in the new emerging economies. 
From venture to development capital 
Nevertheless, raising the necessary venture capital is just 
one step in the long process which leads to the marketing 
of a biotechnological product. Clinical trials and securing 
authorisation require a fresh capital injection. This is what 
is known as development capital, and is usually provided 
by f inancial markets specialising in h igh technologies. 
There are two ways for a company to be launched on 
the stock market in Europe: through one of the five new 
markets (London, Frankfurt, Mi lan, Amsterdam, Paris), 
or directly at European level through the Nasdaq-Europe. 
'These new financial markets have created a very beneficial 
new dynamic, but they remain too f ragmented, ' is the 
view of Philippe de Taxis du Poêt of the Research Direc-
torate-General . Hence the idea of fur ther in tegrat ing 
them through the Financial Service Action Plan. The FSAP 
is a set of 40 measures adopted at the Stockholm Summit 
in March 2001 and due to enter into force by 2005. The 
successful transition to the euro has made this integration 
even more desirable. O 
Equipment at the Computer 
Cell Culture Centre in 
Seneffe (Belgium), 
which specialises in cell 
culture for the production 
of vaccines and other 
therapeutic proteins. 
To f ind out more 
OEuropean Investment Bank 
www.eib.org 
OEuropean Investment Fund 
www.eif.org 
OFuropean Venture Capital 
Association 
www.evca.com 
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One of the Cellectis laboratories. This newly created 
biotechnology company is part of the Pasteur Bio 
Tope business incubator, set up in December 2000. 
© Institut Pasteur 
The number of biotechnology companies in the EU more than doubled 
between 1997 and 2 0 0 1 . Today, 1 8 7 9 companies employ 87 182 workers. 
This record growth - the highest in the wor ld during this period - reflects 
Europe's new biotech dynamic having been left behind by the Americans 
for a long t ime. 
A wealth of 
It is happen ing all over Europe. Whi le it was UK 
start-ups wh ich led the field unt i l the mid-1990s -
w i th one-quarter of the firms and one-th i rd of the 
capitalisation - today's European biotech landscape 
is mu l t i po la r . Germany , the Un i ted K i n g d o m , 
France, Scandinavia, the Netherlands and Belgium 
each have more than 150 biotechnology companies. 
Biotech and high tech 
This ' b io tech b o o m ' has b r o u g h t w i t h it some 
major quali tat ive changes. Unti l the mid-1 990s, the 
term b io technology was applied to all companies 
work ing on l iving organisms, as dist inct f rom the 
t rad i t iona l pharmaceut i ca l and chemica l sector. 
Progress in research and techno log ica l transfer 
have n o w blurred that d is t inct ion. In add i t ion to 
the ' t rad i t iona l ' specialities (such as enzyme pro-
duct ion th rough bacterial fermentat ion) there are 
n o w new act ivi t ies requ i r ing advanced research 
and high-tech tools, such as genome research for 
therapeutic purposes. 
Mirror ing the t rend in the informat ion and c o m m u -
n ica t ion technolog ies , this changed life science 
landscape, characterised by a weal th of h igh-tech 
star t -ups, has radical ly al tered the re lat ionship 
between SMEs and major companies, in this case 
pharmaceutical, agricultural and chemical. The latter 
were the pioneers unt i l the 1980s, deve lop ing 
biotechnologies w i th in their o w n research depart-
ments . But the dynamism of the b io techno logy 
SMEs - often provided by the cream of academic 
researchers - has convinced the 'giants' to pursue 
another strategy and to set up partnerships and net-
works w i th the most creative SMEs. 
These partnerships are clearly mutual ly beneficial: 
the start-up gains access to research funds and the 
large company acquires new technologies which it 
does not have the means to develop itself. Will this 
© Crop Design 
Cereals of the future 
It was in Ghent, Belgium, that in the early 1980s Marc Van Montagu's 
pioneering team developed their first transgenic plants. The city has 
retained its agri-biotech tradition and is now home to Crop Design, one 
of the most important European start-ups in this sector. With its roots in 
the Flemish Inter-University Institute for Biotechnology, and founded in 
1998, the company now employs more than 70 persons in its 1 400 m2 
of laboratory space. It has also managed to raise €30 million in a 
two-stage capital increase. 
So how did Crop Design manage to convince the venture capitalists? By 
pressing home the environmental benefits of the new generation of 
GMOs on which it is currently working, obtained by modifying the gene 
expression within the plant rather than by adding new genes. Under the 
Nonema European programme - on which nine academic laboratories are 
cooperating - Crop Design is also carrying out research on the auto-
stimulation of plant defence systems against nematodes. 
These worms attack the plant roots causing damage to crops estimated at 
€80 billion a year worldwide. The only available means of combating 
them at present is with chemicals which are not biodegradable and thus 
build up in the environment. An interesting alternative would be to stim-
ulate the expression of certain nematode-resistant genes in the roots 
only, and then only in the event of attack by this parasite. 
The Traitmill technology developed by Crop Design, which makes it 
possible to predict the effect of various genetic modifications on the 
development and agronomic qualities of the plant, is the design tool of 
the 'greener' generation of GMOs of tomorrow. 
Owww.cropdesign.com 
Owww.nonema.uni-kiel.de/ 
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trend ultimately lead biotech start-ups to opt for 
independence and to start competing with the large 
groups? Or, once the genetic revolution is over, will 
we see the big groups buying out the outsiders, the 
dynamics of the start-ups being a temporary though 
highly efficient form of research? 
start-ups 
All-purpose enzymes 
Enzymes - proteins which act as a 
catalyst for chemical reactions by 
b ind ing specifically to one or 
more molecules - are very 
much the 'all-purpose' tool. 
They are found in pathogen 
de tec t ion kits, the paper 
industry and biosensors, for 
example . The difficulty lies 
in purifying t h e m while at 
the same t ime preserving 
their biological activity. This 
is the principal activity of the 
British c o m p a n y Applied 
Enzyme Technology (AET) based in Pontypool in South Wales. Its 
chemists, biologists and physicists are all dedicated to the same goal: 
to control the enzyme's molecular environment so as to stabilise it 
while retaining its catalytic properties. The approach has already 
been applied successfully to more t h a n 50 proteins, in particular 
as part of the European Diamonds (Directly Interfaced And Micro Or 
Nanostructured Detection Systems) project which the AET coordi-
nated between 1997 and 2000. As this established the feasibility of 
the nano-technological approach, the next step is to develop appli-
cations. AET has thus joined the Safeguard (Sensor Arrays For Envi-
ronmental , Generic And Routine Detection of Pesticides), project 
which is seeking to use immobilised enzymes as ultrasensitive sensors 
to detect pollutants. 
Owww.aetltd.com 
OOn the Safeguard project: 
http://europa.eu.int/comm/research/quality-of-life/cell-factory/volumel/projects/qlk3-2000-
00481_en.html 
The Union: new aid 
Whichever proves to be the case, following the very 
strong growth over the past five years in Europe, 
consolidation is now needed. In terms of start-up 
numbers, the gap opened up by the United States 
may have closed, but the companies are too new to 
create revenue which is in any way comparable 
with the sums being generated across the Atlantic: 
€9.87 billion in Europe compared with €1 3.73 billion 
in the United States. The sector is struggling to 
achieve economic stability due to the scale of the 
initial investments in research. In 2001, total losses 
recorded for the sector in Europe amounted to 
€1.52 billion. Meanwhile, new products developed 
by US companies are now winning market shares 
which are earning them considerable revenue. 
To support European genome research and its appli-
cations in the field of health, under the Sixth Frame-
work Programme 2002-2006, a budget of €2255 mil-
lion will be allocated mainly to aid integrated 
projects and to set up networks of excellence. Of 
this, 15% - or €338 million - will be devoted to 
integration of SMEs. 
Consolidation also involves strengthening links 
between the individual biotechnology companies, 
in particular through partnerships or mergers 
between firms developing complementary tech-
nologies. 'A working group is being set up which 
will bring together the European Investment Bank 
and venture capitalists,' confirms Waldemar Kütt of 
the Research Directorate-General. 'This will look at 
new financing models to consolidate the growth of 
Europe's biotech industry in the longer term.' 
The virtuous circle 
of the 'biovalleys' 
Any moves to strengthen European biotechnologies 
must also study the circumstances which gave rise 
to their creation in the first place. 'Clearly the vast 
majority of European start-ups originated in a local 
context in the immediate vicinity of research centres. 
In many regions this was encouraged by a committed 
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To find out more 
OBioMAG 
www.bio-m.de 
OGenopoles network 
www.genopole.org 
OManchester Bioscience Incubator 
www.bionowxo.uk 
Olhe Rhine Biovalley 
www. biovalley.com 
policy to create biovalleys,' explains Phlippe de 
Taxis du Poet. Biovalleys are a geographica l 
concentrat ion of high-tech companies around a 
local project for economic development, such 
as the BioM AG Munich Biotech development 
in Germany, the Manchester Bioscience Incuba-
tor in the United Kingdom, the Evry genopole 
in France, or the Biovalley - which has regis-
tered its name as a trademark - straddling the 
three countries of the Rhine Valley (Germany, 
France, Switzerland). 
Why have companies concentrated in these 
areas? 'Because they not only find scientific 
excellence but also a stimulating environment 
offering them the means to evaluate the com-
mercial potential of an idea or a technology, 
to conduct a market analysis, to create a man-
agerial team and to seek finance, in particular 
start-up capital. These are all necessary to 
launch a business,' continues Philippe de 
Taxis du Poet. 'The biovalleys are therefore 
attracting innovative companies which in turn 
make the environment even more attractive, 
creating a virtuous circle which strengthens 
the link between the ability to discover and 
the ability to find commercial applications.' 
It is a model which has proved its worth. It 
must now be disseminated and improved by 
networking and more generally facilitating 
exchanges of experience between biovalleys. 
'The instruments of the new Framework Pro-
gramme are open to any proposal to this 
effect,' confirms Waldemar Kütt. O 
Medicon Valley 
© NeuroSearch 
The densest concentration of biotechnology companies is found in 
the northern EU countries, between the Copenhagen (DK) area and 
Skania in Sweden. This Medicon Valley has 26 hospitals and 12 uni-
versities with 4 000 researchers and 135 000 students. It combines 
academic excellence with economic success, providing 30 000 jobs in 
more than 160 biotechnology companies, some of which, such as 
Denmark's Neurosearch - devoted to the quest for medicines to treat 
complaints of the central nervous system - have become genuine 
pharmaceutical 'strongholds'. The secret of such success clearly lies 
in the concentration in the same area of scientific excellence, a high-
tech industrial fabric, a highly skilled workforce and a coherent strategy 
of government aid. But most important of all is the commitment to 
cross-border co-operation. 
It all started at the end of the 1980s at a time when southern Sweden 
was being hit hard by the closure of its shipyards and textile mills. 
The Ideon Science Park opened alongside the University of Lund 
campus, its founders taking their inspiration from the US model of 
research centres and companies in close proximity, as in Silicon valley. 
At the same time, across the Øresund Straits, Danish researchers 
returned from a trip to the United States and founded the Medicon 
Valley Academy, a binational non-profit-making institution 
charged with the coordinated development of the dual site. Today 
the Medicon valley is attracting US companies, and Biogen of 
Cambridge, Massachusetts plans to set up its first European plant 
there - with the prospect of €350 million in investments and the 
hire of 400 employees by 2005. 
Owww.mediconvalley.com 
O www. neurosearch .com 
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As the decade begins, biotechnology presents Europe wi th a strategic choice. It can follow - and 
be subject to - innovations developed elsewhere, or it can anticipate them for its maximum benefit , 
and to guide them in a way which Europeans would want . To face this challenge, the Union needs 
a shared and coherent vision and approach. This is exactly wha t the Life sciences and biotechnology, 
a strategy for Europe communication and action plan - prepared by the Commission and approved by 
the Barcelona European Council - aims to do. 
Decision time for 
the Union 
At the Lisbon Summit in March 2000, European heads of state 
and government set the goal of 'making Europe the most com-
petitive knowledge-based economy in the world by 2010'. The 
following year, the Stockholm Summit confirmed this ambition 
and stressed the importance of biotechnology in achieving it. 
The Commission was charged with developing the strategy. A 
first consultation paper was circulated in September 2001. That 
autumn, 320 contributions were received from governments, 
the European Group on Ethics (EGE), industrialists, researchers 
and individual citizens. These were all taken into account when 
drafting the final document, published in January 2002 and 
submitted in March to European leaders gathered in Barcelona. 
This strategic vision is rooted in an inescapable fact: although 
Europe has a solid skills base in the life sciences, the use it makes 
of this scientific excellence falls far short of US performances in 
this sector. The Commission document states that one of 
Europe's major weaknesses is that 'total European investment in 
research and development lags behind that of the United 
States. Europe also suffers from the fragmented nature of aid 
to public research as well as the low level of inter-regional 
co-operation in research and development between companies 
and institutions in different regions of several Member States.' 
Thus, the lack of common goals and a shared vision of what is 
really at stake has meant that Europe has been slow to seize the 
challenges and opportunities of the new biotechnological age. 
Strengthening the knowledge base 
To correct the situation, Europe must first improve its capacity 
to use the potential advantages of these technologies by devel-
oping concrete research and development. 'When Europe 
works together, it is strong,' stated European Research Commis-
sioner Philippe Busquin at the Biovision Forum (Lyon, February 
2001), citing the example of European co-operation in genome 
sequencing. But he also added that 'aid to European coordination 
With sound know-how 
in the life sciences, Europe 
has not yet managed to 
draw maximum benefit 
from its scientific excellence, 
in particular as a result of 
the fragmentation of financial 
and human resources. 
© NeuroSearch 
will also be important in the case of key emerging technologies, 
such as those promised by research on stem cells, xenotrans-
plantation, nanobiotechnology and proteomics. 
The Sixth Framework Programme (2002-2006), now finally 
adopted by the Union, is designed to be a key instrument in 
supporting this research. It includes two thematic priorities (Life 
sciences, genomics and biotechnology for health - with a budget 
of €2 255 million euros, and Food quality and safety - €685 mil-
lion) which will be fully open to biotechnology while two others 
will have recourse to it (Nanotechnologies and Sustainable devel-
opment and global change). This thematic concentration will be 
further strengthened by the very nature of the support which 
will be aimed above all at the implementation of integrated pro-
jects and the creation of networks of excellence able to generate 
co-operation throughout the European Research Area. Other 
programmes - such as support for SMEs and innovation, for 
the mobility of researchers, and for scientific infrastructures -
will also encourage this mobilisation. 
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To find out more 
ODocument A strategy lor Europe 
http://europa.eu.int/comni/ 
biotechnology/introduction_en.html 
Olhe European Group 
on Lile Sciences 
http://europa.eu.int/comm/research/ 
llfe­sciences/egls/index en.html 
OThe European Group on Ethics 
http://europa.ej.int/comm/ 
european group__ethics/index en.htiii 
Olhe European Research Area 
www. europa, eu. ¡nt./comm/research/ 
era/index_en.html 
Olhe Sixth Framework Programme 
www.europa.eu.int/comm/research/ 
fp6/index en.html 
OEuropean Organisation 
lor Molecular Biology 
www.embo.org 
GMOs: α social issue taken into account by one of the principles of European strategy: responsible governance 
of the life sciences and biotechnology. Above, colza microplots for research on herbicide-resistant plants. 
© ¡.Casqueζ 
Ethical vigilance 
This aid for research and innovation must not, however, 
conceal another key aspect of the biotechnological revolu­
t ion: the need to exercise control over the ethical and 
social choices presented by the applications generated by 
this new knowledge. In Europe, as elsewhere, develop­
ment must be clearly in line wi th the sensitivities of society. 
If no t , the who le dynamic cou ld be lost. Hence the 
importance of the second principle of European strategy: 
responsible governance of lhe life sciences and biotechnology. 
The present subjects for public debate range from geneti­
cally modif ied foods to the use of embryonic human stem 
cells, these issues representing just some of the changes 
brought about by progress in the life sciences. The aim of 
forums for dialogue w i th society, such as those organised 
by the European group for life sciences, ( ') is to broaden the 
discussion by presenting well­ founded hopes in terms of 
combat ing diseases and hunger in the wor ld . This group 
has already organised two open conferences on genetics, 
and stem cells. Its next forum wil l look at the contr ibut ion 
of the life sciences to sustainable agriculture in Developing 
countries. Other bodies wil l be asked to participate in the 
interests of impartial vigilance, such as the European Croup 
on Ethics. Finally, the seventh priori ty axis of the Sixth 
Framework Programme, Citizens and governance in a 
knowledge-based society, wi l l f inance research on the 
socio­economic impact of biotechnology. 
Rhythm and regulations 
Encouraging society's suppor t for b io techno logy also 
means gett ing the products of b iotechnology on to the 
market as quickly as possible. 'We must ensure that new 
products are safe for the consumer and the envi ronment 
while at the same t ime providing the clarity and visibility 
which the societies which market them need so much , ' 
explained Philippe Busquin at the Biovision Forum. New 
more coherent rules that are standardised at European 
level wi l l therefore apply t o the distr ibut ion of new medi­
cines, such as condit ional authorisation for one year and 
an accelerated examination of files on products of impor­
tance to publ ic heal th . The regulat ions govern ing 
agri­biotechnology wil l also see some changes w i th the 
harmonisation of legislation on the use of GMOs in animal 
feedingstuffs, their detect ion, and the moni tor ing of any 
risks (or benefits) for the environment. In all cases the 
approach is the same: to reduce the marg in of uncer­
tainty surrounding the risks and benefits, and to provide 
objective facts as a basis for regulated mon i to r ing w i t h a 
view to international recogni t ion. 
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'The life sciences and biotechnology are not a panacea and will not solve problems of distribution affecting the developing world. 
But they are one of the major instruments for so doing. ' 
© INSERM 
An international vision 
As the biotechnological revolution concerns the whole 
planet, there is a need to 'respond to this global chal-
lenge' - the third strand of European strategy - through 
international dialogue on regulatory matters, in particular 
w i t h i n mul t i la teral fo rums such as the Wor ld Trade 
Organisation (WTO), the Protocol on Biosecurity, or the 
various UN agencies. It is wi th in these bodies that such 
issues must be debated if the Union is to play a leading 
role in setting a course, standards and recommendations 
on the basis of international scientific consensus. 
The international approach must also take into account 
its special responsibility towards developing countries. 
The biotechnologies offer many new opportuni t ies for 
p rov id ing g lobal f o o d securi ty, comba t i ng Aids and 
preserving biodiversity. 'The life sciences and biotechnol-
ogy are not a panacea and wil l not resolve the problems 
of distr ibut ion affecting the developing wor ld . On the 
other hand , they wi l l be one of the inst ruments in 
achieving this,' states the Commission's strategic docu-
ment. Through increased scientific co-operation, Europe 
must help the developing countries to manage the risks, 
challenges and possibilities of these new technologies, 
in accordance w i t h the choices made by each one 
of them. (2) 
The adopt ion of this European strategy wil l serve as a 
reference for meet ing the challenges presented by the 
explosion in the life sciences. It is nevertheless difficult 
today to say what wil l be the questions raised by devel-
opments in b iotechnologies over the next five or ten 
years. This is why the Commission wants to receive regular 
reports on the coherence of EU policies and legislation. 
All those w i th a stake in European biotechnologies are 
already invited to participate in the refining and imple-
mentat ion of the initiatives proposed. O 
(/) See site in margin. 
(2) See the article on the EDCTP initiative on clinical trials in Africa, page 34. 
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Five European laboratories have teamed up to work on a fascinating project to study 
the oceans' smallest inhabitants. We now know that these minute microcellular 
creatures play a key role in maintaining some of the world's major ecological balances. 
The lilliputians 
Sampling picoplankton in 
the coastal waters close to 
Roscoff (France). 
© D. Doussal - Roscoff 
Biological Station 
Contact 
ODaniel Vaulot 
vaulolOsb roscoll.lr 
Biological Station. CNRS and UPMC 
Oceanic Phytoplanklon learn. 
BP 74. 29682 Roscolf. France 
Internet site 
Owww.sb-roscoll.lr/Phyto/PICODIV/ 
Picoplankton? We encounter them all the t ime. The tiniest 
drop of sea water is teeming wi th these organisms less 
than three microns in size.(') Every t ime we take a d ip, 
we are surrounded by billions of picoplanktonic cells. 
These minute creatures - 25 years ago we did not even 
know they existed - remain an enigma. The European 
Picodiv pro ject (Exploring the picoplankton diversity) 
aims to shed l ight on some of the mystery w h i c h 
surrounds this whole swathe of living creatures, concen-
t rat ing in part icular on phytosynthet ic eucaryotes, (2) 
the picoplankton about wh ich we know least of al l . 
Similar but different 
'To date we have identified around 4 000 species of tradi-
tional phytoplankton. These are visible to the naked eye 
and commonly measure around 100 pm", as in the case 
of d iatomea, for example, a very abundant species of 
unicellular algae,' explains Daniel Vaulot, a researcher 
at the Roscoff Biological Station in Roscoff, France and 
co-ord ina to r of the Picodiv project . 'But on ly abou t 
30 species of p icophytoplankton have been described. 
This is a derisory figure as we suspect there are a great 
many species of these truly minute organisms.' Picophagus 
flagellatus (described in 2000) measures around 2 f im, 
while the very abundant Prochlorococcus marinus, is among 
the smallest at just 0.5 pm. 
To complicate matters, these oceanic lilliputians have the 
annoying tendency of resembling one another. Many are 
spherical in shape and green or brown in colour. This sim-
ilarity does not, however, prevent them from displaying 
big differences in metabolism, environmental preferences, 
dynamism, pigments and other proteins. In short, they 
may look the same bu t they are in fact qu i te d i f ferent . 
'To describe a unicellular organism, in principle you have 
to be able to cultivate it, ' continues Daniel Vaulot. 'The 
s i tuat ion is fur ther compl i ca ted w i t h p icop lank ton 
because the usual nutr i t ional environments always select 
the same species, wh ich proli ferate at the expense of 
those we are interested in. So we must take great pains to 
refine our culture mediums. We have achieved this w i th 
some success, but still have a long way to go . ' 
The latest molecular tools 
Researchers are therefore using new techniques to try to 
penetrate the mysteries of picoplanktonic diversity, turning 
in particular to the latest advances in molecular biology. 
Carlos Pedros-Alio, of the Instituto de Ciencies del Mar in 
Barcelona, is one of the experts on these genetic tools 
wi th the Picodiv team. 'Even if a species is not described 
in the traditional sense, we can obtain a genetic signature,' 
he explains. 'We have succeeded in iden t i f y ing very 
variable zones in the genome of these micro-organisms, 
more specifically in the sequence of the 18S ribosomal 
RNA gene. When two individuals show very di f ferent 
sequences in these zones, we can consider tha t they 
belong to different species, al though it is not really very 
accurate to speak in terms of species for such minute 
creatures. When the differences exceed a certain l imit, 
we consider they be long to d is t inct genres or classes.' 
These signatures make it possible to detect changes in 
the compos i t ion of p icoplanktonic commun i t i es . The 
so-called Denaturing Gradient Gel Electrophoresis (DGGE) 
technique is then applied. The 18S RNA gene is amplif ied 
in a seawater sample and deposited on a gel which is then 
subjected to an electric current causing the molecules to 
migrate. The result is a series of bands w h i c h fo rm 
a fingerprint defining a given populat ion. By using this 
tool , researchers are able to determine how, depending 
on the place and t ime of year, dif ferent p icop lankton 
varieties succeed one another in the marine environment. 
Also, it is now possible to count picoplankton, to define 
the density of a particular species. The method , known as 
Fish (Fluorescent In Situ Hybridisation) is qui te simple. 
M A R I N E B I O D I V E R S I T Y RTD info N° 35 October 2002 15 
Diatomea and dinoflagellae are species 
of 'traditional' phytoplankton 
(in the 20 to 200 pm range), which bloom 
in spring and summer. 
© D. Vaulot - Roscoff Biological Station 
of the plankton world 
'We prepare small quantities of DNA designed to fasten 
on to the signature of a given species,' continues Carlos 
Pedros-Alio. 'We then add a small fluorescent molecule. 
When this DNA solution is mixed with a sample taken 
from the ocean, a comparison between the proportion of 
fluorescent individuals and the total population (that can 
be counted under the microscope) gives us the proportion 
of the variety we are interested in.' 
Bringing back the bounty 
Finding out more about picoplankton could bring many 
benefits. There is certainly a fundamental aspect relating 
to knowledge of the life sciences. 'There are very complete 
catalogues of stars, some of which are millions of light 
years away,' stresses Carlos Pedros-Alio. 'It would be 
paradoxical not to know something about the popula-
tions of the water in which we bathe.' 
Participants in the Picodiv project regularly work at three 
sampling sites, chosen as representative of the diversity of 
European coastal waters: Roscoff (Channel), Helgoland 
(North Sea) and the Bay of Blånes (Mediterranean). They 
also take part in a lot of marine expeditions, from the 
Arctic to the South Pacific. 'We sometimes have the 
impression we are working in the European tradition of 
the great 17th century naturalists who returned from 
every trip with new and extraordinary species and laid 
the foundations for the taxonomy of living organisms,' 
adds Carlos Pedros-Alio. 
Climate sentinels 
Important discoveries concerning the biology of this 
whole layer of life are already in prospect. According to 
Daniel Vaulot, ' heterotrophic eucaryotes (those without 
chlorophyll) used to be considered exclusively as preda-
tors. We now believe their role could be much more 
complex and varied, ranging from breaking down 
organic material to parasitism - none of which was sus-
pected five years ago. In some waters, the picoplankton 
represent 80% of the biomass and play a determining 
ecological role at global level. Not only are they at the 
base of the food chain, but they are also involved in 
essential cycles of matter, especially of carbon or nitrogen. 
This means that a sound knowledge of the biology of 
picoplankton is essential for an accurate modelling of 
climate development.' When the associated species have 
been identified (in warmer waters or in waters rich in a 
given nutrient, for example), a simple sampling will tell 
us whether these indicator organisms are present. 
Some species of picoplankton are also known to be toxic, 
so it is better to have tools with which to detect them. 
'In this new field of research, co-operation between 
European laboratories gives us the critical mass needed 
to hold our own in the face of the US teams,' stresses 
Daniel Vaulot. 'In a sense, we are the pioneers of the 
study of small eucaryotes, a field that is proving very 
fruitful.' It is not for nothing that the work of the Picodiv 
researchers has been featured in the pages of Nature on 
a number of occasions. O 
(1) Three thousandths of a millimetre, or 3 pm. 
(2) Eucaryotes are cells with a genuine nucleus, unlike bacteria. 
16 RTD in fo N° 35 October 2 0 0 2 S U S T A I N A B L E D E V E L O P M E N T 
Revealing the hidden 
S U S Τ A I N A D E V E L O P M E N T 
Europe has made a determined choice towards a policy of 
sustainable development. To be effective, this must involve a 
review of economic calculations to include previously ignored 
costs. If these 'externalities' were to be taken into account in 
the energy field, the price per kWh of fuel of petroleum origin 
would double. The ExternE, NewExt and ExternePol projects 
have developed a remarkable methodology which serves as 
a reference for this new kind of cost calculation. 
Known as externalities, these hidden costs relate mainly to 
health and environmental expectations. Burning one tonne of 
coal at a fossil­fuelled power station, for example, results in the 
emission of many substances into the atmosphere. These have 
various effects within the perimeter around the emission point, 
including an increase in respiratory diseases, deterioration of 
buildings and lower agricultural production. 
The impact pathway 
Although the principle may seem obvious, implementatior 
is particularly complex. It began in the early 1990s at a time 
when the term sustainable was being used increasingly in political 
circles without anyone being able to lend it any real scientific 
substance based on sound principles of evaluation. The ExternE 
­ External Costs of Energy- project was originally launched by a 
For the community these negative effects are costs which are 
not included in the energy bill as such. Some feed through to 
quantifiable sums in other sectors, such as health care. Others 
are more 'virtual' in nature but can be estimated nevertheless in 
terms of the price citizens would be prepared to pay to avoid 
them. There is a growing urgency to make a rigorous evaluation 
of all these externalities as they are a valuable decision­making 
tool when making major political and economic choices in the 
field of energy policy. 
The external costs of electricity production in Europe vary from one 
European country to another depending on technological and 
demographic differences. In Germany, for example, the external cost 
per kWh produced by a windmill is 0.05 cents compared with between 
S and 8 cents for electricity produced by an oil-fuelled power station. 
consortium of European and American researchers.Ç) The aim 
was to define energy externalities ­ and more precisely electricity 
production externalities ­ for each of the available sources: 
wind, solar, nuclear, biomass, coal, oi l, natural gas, and 
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hydroelectric. 'The project required the co­operation of 
many specialists from different disciplines: economists, 
physicists, chemists, epidemiologists and ecologisti,' 
explains Ari Rabl, one of the ExternE directors and a 
researcher with the Energy Centre at the Ecole des Mines 
in Paris. 'It was a fascinating exercise intellectually as 
everybody had to become something of an expert in 
everything to understand exactly what their colleagues 
expected of them.' 
The method developed, known as the impact pathway, is 
a logical and systematic approach. It estimates the cost of 
each and every stage in electricity production, bar none. 
In the case of coal, for example, this involves evaluating 
the impact of building a new thermal power station, min­
ing the raw material and quarrying the limestone (when 
used for flue gas desulphurisation), transporting the coal, 
wastes and other materials, the electricity generation 
itself, waste disposal and electricity transmission. 
J 
Variable geometry totals 
'A sound evaluation of impact in monetary terms requires 
knowledge which has only been acquired over the past 
decade and without which ExternE would not have been 
possible,' stresses Ari Rabl. 'We have used recent epi­
demiological data to asses the impact on health ­ in 
terms of the number of persons affected and number of 
years of life lost ­ of certain pollutants. We have also used 
models for the dispersion of pollutants in the air, at local 
and European level.' 
The mass of data which the ExternE methodology took 
as a basis for its conclusions is impressive. They range 
from technical elements, such as emission levels for each 
pollutant (several dozen were taken into account), to 
meteorological models, which are essential for assessing 
dispersion, and include demographic data and surveys 
of individual value systems so as to quantify notions such 
as impaired health. 
After eight years of study involving dozens of researchers 
throughout the Union, dating from 1998, ExternE has 
drawn up an inventory per country and per energy. The 
picture which emerges isa varied one.(2) In Germany, for 
example, the external cost per kWh produced by wind 
power is 0.05 cents, compared with 5­8 cents per kWh 
for electricity produced by an oil­burning power station. 
ExternE Transport 
Although ExternE focused on electricity production, some of the 
results obtained can be used for other evaluations. A group of 
researchers, led by Peter Bickel of Stuttgart University, decided to 
apply the impact pathway methodology to transport. A series of case 
studies were carried out on road transport (using various fuels), as well 
as on waterways and rail transport in a number of countries. 'The 
impact on health dominates the quantified damage in our study, in 
particular mortality due to primary and secondary particles such as 
nitrates and sulphates. We have also established that population 
density in the vicinity of roads is a determining parameter for the 
scale of the impact,' believes Peter Bickel. The researchers were rather 
surprised to find that carcinogenics emitted by vehicles are less harmful 
than particles, mainly emitted by diesel engines. A comparison of 
the externalities of freight transport by road and rail shows that the 
former amount to between €0.04 and €0.3 tonnes/kilometre and 
the latter between €0.001 and €0.009 tonnes/kilometre. 
www. feem. it/gnee/terapap/bickel. html 
The EcoSense software 
The ExternE team has developed EcoSense, an externalities evaluation 
software of potential interest to a number of users. The principle is 
simple: once the damage caused by one tonne of sulphur dioxide has 
been calculated, for example, this figure can then be used rapidly by 
relating it to the population exposed. Brazil and China are among the 
countries which have started studying their externalities using 
EcoSense. It has also been used by the electricity company EDF 
(Electricité de France). The researchers plan to update the software 
regularly and make it more readily available. 
externe, ¡re. es/Method+EcoSense.htm 
18 k I \> i n f o N " 3 5 O c t o b e r 2 0 0 2 S U S T A I N A B L E D E V E L O P M E N T 
To find out more 
OOlficial ExternE site 
with 1998 results: 
http://externe.jrc.es/ 
OAnother site with a wealth 
of information: 
www.exlerne.inlo/ 
OThe NewExt site, hosted 
by the University ol Stuttgart: 
www.ier.unisliittgart.de/ 
public/all t/ttu/projekte/newext/ 
newxmenu.html 
The risk of technological accident -
oil spills, burst dams, etc. - is also 
included in these calculations. 
Primarily taken into account 
for nuclear power, these costs 
are low as a result of the existing 
safety measures. 
Throughout Europe, the external costs of the nuclear kWh - ten 
times less than for coal - are low, ranging from 0.2 to 0.7 cents. 
As a rule, the differences between countries are considerable, 
reflecting differences in the technology used as well as demo-
graphic differences. Researchers consider that the external costs 
of electricity product ion are equivalent to 1-2% of Europe's 
GDP. They also believe that if these costs were bil led, the price 
per kWh of energy p roduced f rom oil or coal w o u l d doub le . 
ExternE follow-up 
These results, as well as the solid interdisciplinary and scientific 
methodology used to compile them, are the first of their kind to 
be published and have already been accepted as a reference for 
energy policy in the med ium to long term. At the same t ime, 
work is cont inuing on further refining this methodo logy under 
an ExternE fol low-up project known as NewExt or, to give its full 
name, New Elements for the Assessment of External Costs from 
External costs of electricity production in the EU 
Sub-totals of quantifiable externalities in terms of public health, occupational diseases, material 
damage, climate warming, etc. (in cents/kWh). , 
Country 
AU 
BE 
OE 
DK 
ES 
Fl 
FR 
GR 
IE 
IT 
NL 
NO 
PT 
SE 
UK 
Coal Lignite 
4-15 
3-6 
4-7 
5-8 
2-4 
7-10 
5-8 
6-8 
3-4 
4-7 
2-4 
4-7 
Peat 
2-5 
3-4 
Oil 
5-8 
8-11 
3-5 
3-6 
3-5 
Natural gas 
1-3 
1-2 
1-2 
2-3 
1-2 
2-4 
1 
2-3 
1-2 
1-2 
1-2 
1-2 
Nuclear 
0.5 
0.2 
0.3 
0.7 
0.25 
Biomass 
2-3 
3 
1 
3-5* 
1 
1 
0-0.8 
0.5 
0.2 
1-2 
0.3 
1 
Hydro-electricity 
0.1 
1 
1 
0.3 
0.2 
0.03 
0-0.7 
Photovoltaic 
0.6 
Wind 
0.05 
0.1 
0.2 
0.25 
0-0.25 
0.15 
* mixed biomass-lignite combustion 
Source: ExternE 
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Energy Technologies. This aims to refine certain parameters, in 
particular the evaluation of the monetary costs of mortality due 
to atmospheric pollution. The externalities will also be extended 
to include areas not yet taken into account, such as damage to 
soil and water (acidification and eutrophication, dioxin emis-
sions, influence of each energy on global warming, etc.). 
Researchers are also busy exploring the externalities resulting 
from the risk of technological accident. Previously these were 
calculated principally for nuclear energy, but given the high 
level of safety and the high degree of 'improbability' of an 
accident at a European nuclear power station, they proved to 
be very low. To provide a balanced picture for all energies, how-
ever, the probability and costs of catastrophes such as oil spills 
or the bursting of dams should also be taken into account. 
Will the NewExt results - available next year - change the 
picture presented by ExternE? 'It is still too early to say,' says 
Alexander Gressmann of Stuttgart University, one of the 
NewExt coordinators. 'In a sense, the more we try to quantify 
new and ever more complex externalities, the more we cause 
the hidden costs to rise. But on the other hand, by refining our 
calculation instruments (statistical tools for evaluating mortality, 
for example) we reduce other amounts.' 
How does it translate into policy? 
The study of externalities involves a continuous process of 
updating as progress is made in the various disciplines involved. 
This will be one of the tasks of ExternePol which, from autumn 
2002, will also be building on the work begun by ExternE. 'We 
want to increase the reliability of results, such as by incorporat-
ing new and better models. We also want to extend the 
methodology so that it can be applied to new problems,' 
explains Ari Rabi, who will be the project coordinator. 
ExternePol (as its name suggests) will also try and improve the 
communication of the results obtained over the past decade to 
policy-makers and ensure that they can use them as a tool in the 
service of sustainable development. 
One possible policy measure would be to tax the energy 
sources most damaging for society in accordance with the costs 
they create. However, this would mean a rise in energy prices 
producing damaging effects in other areas of the economy; it is 
also difficult to apply a homogenous tax throughout the EU. 
Another approach would be to subsidise energies which use 
clean technologies. A Community text adopted in February 
2001, for example, authorises 'Member States to grant operat-
ing subsidies to new installations producing renewable energy, 
calculated on the basis of external costs'. These subsidies are 
currently limited to 5 rents per kWh. 
'We are seeking to change mentalities,' stresses Ari Rabl. 'This 
process takes time. But a number of countries have expressed 
interest in our work, dozens of studies have adopted our 
method and our results have been taken into account when 
drawing up European directives. Personally, I have even been 
approached by several industrialists seeking an externalities 
calculation for their plant. These are all signs that our work is 
gaining recognition.' O 
(1) The Americans pulled out of the project in 1995. 
(2) The results are available at http://externe.jrc.es 
The value of years lost 
In the field of health and the environment, the NewKxl researchers 
have replaced the traditional concept of a calculation based on the 
Value of Statistical Life with an evaluation of the Value of Life Year Lost. 
'We see this approach as very pertinent,' explains Alexander Gress-
mann. 'Atmospheric pollution usually has the effect of reducing aver-
age life expectancy by several months due to the appearance of certain 
chronic diseases.' These cannot be calculated in the same way as fatal 
accidents - such as road accidents - which on average shorten a life by 
several decades. 'These concepts may seem cynical for non-econo-
mists,' concludes the NewExt coordinator. 'In reality, they arc simply 
tools designed to express the economic choices of society as accurately 
as possible.' 
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Miniaturisation, innovative materials, robotics, optics, software engineer ing. . . Despite what some 
people think, space research is at the origin of many technological advances. It is a particular 
source of inspiration for high-tech SMEs seeking to convert innovative technology into commercial 
applications in fields as diverse as medicine, mechanical engineering, transport and textiles. This is 
why the European Space Agency (ESA) has teamed up wi th the European Commission to create 
Esinet, the European network of 'space incubators'. 
On Earth as in the 
When he began his career as a researcher at Brunei 
University, to the west of London, Tony Arson proba-
bly never imagined that one day he would be running 
his own company. Today he heads Anson Medical, an 
SME and member of a group quoted on the Stock 
Exchange. It was while working on a space project in 
the field of microgravity that he realised that shape 
memory nickel-titanium alloys could have interesting 
applications in the medical sector. 'Their principal 
property is the ability to return to their original shape 
following heat deformation, as well as their super elas-
ticity,' he explains. 'Thanks to the support of companies 
specialising in technology transfer, such as |PR in the 
United Kingdom and D'Appolonia in Italy, we have 
been able to develop products which are ideal for less 
invasive surgery, such as orthodontic springs, clips/ 
staples and artificial hips. More recently we have 
developed stint grafts for the treatment of aneurysm. 
This is now our flagship product.' 
As a field of very advanced experimentation requiring 
innovative technological systems, space is a potential 
source of all kinds of applications. As early as 1991 the 
ESA launched its active technology transfer pro-
gramme (TTP) charged with promoting space tech-
nologies in other industrial sectors. Today, more than 
150 technologies with their origin in space have found 
the most diverse applications, generating a turnover estimated at 
€200 million. By 2004 this could have grown to a billion euros. 
SME aptitude 
The size and flexibility of SMEs means that they are often the best 
suited to capitalising on these innovations. Many technology consul-
tancy and brokering companies are active on the 'space transfer' 
market and several of them are participating in the Aero-Space Link 
(Aslink) project. This is supported by the European Commission as 
part of its 'Economic intelligence' initiative which is specifically 
targeted at SMEs. Under the Aslink leadership, about 40 proposals 
The ESA's Technology Transfer programme is promoting 
the SpaceHouse concept in the construction sector. 
This is an Invitation to use the exceptional architectural 
possibilities offered by the development - initially for space 
applications - of carbon fibre reinforced plastics or CFRPs. 
©ESA 
involving more than 80 aerospace companies and 180 companies 
artive in other sectors have been selected by various European 
research programmes. 
Lostesc (Leveraging on Space Technologies to Enhance SME 
Competitiveness), another programme promoted jointly by 
the ESA and the Commission, has a similar objective. 
Thanks to the Galileo (see below) or Global 
Monitoring for Environment and Security 
(GMES) space positioning, navigation 
and environmental monitoring systems, 
a range of new services and applications 
are currently being developed. 
These developments are likely to be of 
particular Interest to innovative SMEs. 
©ESA 
Coordinated by the French company Technofi, six con-
sultancy firms - from Austria, Belgium, France, Italy, 
Spain and Portugal - have identified technologies likely 
to find applications outside the space industry with a 
view to promoting them in industrial circles and proposing 
them for finance as co-operative research under the Craft 
programme. About 30 projects were submitted in this 
way during the Fifth Framework Programme and six or 
seven will be submitted under its successor. The Artec 
Aerospace company of Toulouse, for example, has suc-
cessfully drawn on a new technology for vibration 
absorption used during satellite launches to develop 
applications in shipbuilding (such as the Corsica-Conti-
nental ferry), high-speed train wheels, helicopters and 
Formula 1 rear-view mirrors. 
Need fo r protect ion 
In a field as specialised as space technology transfer, the 
creation of spin-offs or start-ups requires a specific infra-
structure for technical assistance and managerial support. 
These are the needs which the 'space incubators' are 
designed to meet. The ESA has set up one of these incu-
bators in the Netherlands, at the heart of its Estec 
research and technology centre in Noordwijk. There are 
almost 20 centres of this kind throughout Europe - in Bel-
gium, Germany, France, Italy, the United Kingdom, Por-
tugal, Finland, Bulgaria, and Ukraine - located in regions 
with a concentration of space-related activities. Since July 
2001, these SME 'guardians' have worked together 
within the European Space Innovation Network (Esinet) 
exchange and co-operation network. 
This initiative, which benefits from Union support, was 
launched by the ESA, the T4Tech Centre of Genoa (IT), 
the European Business Network (EBN), and Wallonia 
Space Logistics (WSL). 
Why such a network? 'Apart from the traditional man-
agerial and infrastructure assistance, space incubators 
have a very specific vocation. Exploring and implementing 
the technological potential in this field requires a particu-
larly specific expertise, in terms of intellectual property 
for example,' explains Franco Malerba. A biophysicist and 
the first Italian to be launched into space, Franco Malerba 
is an active member of the Italian Space Agency and head 
of the new network's Liaison Advisory Committee. 
Galileo and GMES 
'Esinet meets a need for openness and cross-fertilisation 
which is felt by all these European incubating centres,' 
stresses Florence Ghiron, director of WSL, an incubator 
set up in 2001 in Liège (BE). 'We are working on tech-
nology niche markets where you have to go beyond 
the regional level before you can really do business,' 
she explains. 
Esinet is a very timely development as European space 
activity is set to develop a great deal with the opening of 
the Galileo and Global Monitoring for Environment and 
Security (GMES) sites. 'New services and applications 
will be designed to exploit these future space systems in 
the field of positioning, navigation and environmental 
monitoring,' stresses Florence Ghiron. 'Many of these 
developments could be of direct interest to SMEs. We are 
also ready to welcome at our centres any terrestrial 
applications in terms of transfers generated by the imple-
mentation of these systems at European level. These large 
systems will certainly require increased exchanges.' O 
To find out more 
Owww.ansommedical.com/ 
Owww.jratech.co.uk/ 
Owww.esa.int/export/esaCP/ 
ESATHSUM5JC_Benefits_0.html 
Owww.artec-aerospace.fr 
Owww.estec.esa.nl/ 
Owww.t4tech.com/ 
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DNA: 
an excess of patents 
Several thousand patents have been 
awarded to public and private sector 
researchers in the field of DNA 
sequencing alone. In many cases 
these provide protection for all 
sequence use. The Nuffield Council 
on Bioethics (UK) believes that such 
rights should be an exception rather 
than the rule and that too often 
these patents have been awarded 
without respecting the three­pronged 
rule that traditionally governs the 
notion of a discovery, namely that it 
must be new, inventive and also, as 
it ¡s a patent, utilisable. The associa­
tion has just published The ethics of 
patenting DNA, a report in which it 
shows that many patented sequences 
should not have been patented at all 
because they do not satisfy these 
criteria. This study identifies four 
possible uses of DNA sequences (diag­
nostic tests, research, gene therapy 
and the production of therapeutic 
proteins), in each case stating the 
criteria on which a patent application 
should be based. If taken into 
account these criteria would consid­
erably reduce the royalties which are 
easily amassed. 
To find out more: 
www.nuffieldbioethics.org/ 
www.nuffieldbioethics.org/puhlications/ 
ppJOOOOOuORasp 
www.nuffieldbioethics.org/filelibrary/pdf/ 
theeticsofpatentingdna.pdf 
Scientific culture 
in the United States... 
Seventy per cent of Americans admit 
they understand little about research 
and ­ in contrast to the Europeans ­ a 
growing number believe in 'pseudo­
sciences'. 30% of them believe that 
certain unidentified flying objects 
prove the existence of extraterrestrial 
civilisations, but only just over half 
(54%) know that it takes the Earth 24 
hours to rotate on its axis. Yet they 
retain their faith in scientific research, 
which 44% of those interviewed see 
as generating progress (33% believe 
the opposite). 
These are the latest findings of the US 
National Science Foundation which 
every two years carries out a survey on 
US scientific culture. The report also 
notes that a growing number of for­
eign researchers are working in the 
United States (45% in the field of 
engineering) and identifies trends in 
federal aid for research, up by 50% 
for the life sciences and down by 25% 
for physics. 
To find out more: 
www.nsf.gov 
.and in Japan 
Carried out in 15 countries, a mini 
test of ten questions on science puts 
the Danish in the lead (64% of correct 
answers) and the Portuguese last 
(43%), with the Japanese just two 
places ahead, in 13th position. The 
Japanese tend not to be very cul­
tured about science, are generally 
poorly informed ­w i t h the exception 
of environmental issues ­ prefer tele­
vision and the general press to more 
specialised journals, and do not go 
to exhibitions or other educational 
events to do with science. Neverthe­
less, they see the scientific approach 
and its results as positive (the cynical 
would say this is logical given their 
ignorance of it!) and a large majority 
believe that research should be gov­
ernment funded. A majority would also 
like more effort to be made to promote 
public understanding of science. 
These data are taken from a study* 
published in January 2002 by the 
National Institute of Science and 
Technology Policy, attached to the 
Japanese Ministry of Education. 
* The 2001 Survey of Public Attitudes Toward 
and Understanding of Science & Technology 
in Japan. 
European R&D 
expenditure: 
a warning light 
Last June, European Commissioner 
Philippe Busquin repeated his con­
cern following the publication of the 
latest global indicators revealing 
that Europe is falling further behind 
in its investments in research. Euro­
pean investment in R&D in 2000 
was just €164 billion compared with 
€288 billion in the United States. 
This deficit is largely due to lower 
participation by the private sector in 
the total research effort, represent­
ing 56% in Europe compared with 
nearly two­thirds in the United 
States and Japan. 
EUREKA, 
a market-oriented 
network 
At the annual EUREKA ministerial con­
ference, held in Thessaloniki (GR) on 
28 June, 171 new projects were 
announced for a provisional total 
budget of €490 million and 33 
thematic sub­projects were launched 
for an amount of €930 million. This 
brings the total number of ongoing 
EUREKA projects to 71 3 with a total 
investment of €1.3 billion. The Lille­
hammer Award for the Environment 
was awarded to the Care partnership 
(recycling and disposal of computer 
components which are no longer 
used) and the Lynx Award for SMEs 
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But the public authorities share 
responsibility for this private sector 
reluctance as government support for 
company research represents 12.3% 
in the United States compared with 
8.5% for the Union as a whole. 
Philippe Busquin thus repeated the 
ambitious 2010 target for the Euro­
pean Research Area ­ as ratified at 
the Barcelona Summit in March of 
this year ­ of having the EU (and its 
industry in particular) invest 3% of 
GDP in research (as do the Americans 
and Japanese) as opposed to the 
present 1.8% 
To find out more: 
Science and technology indicators 
for the ERA 
europa.eu.int/comm/research/era/stl_en.html 
went to the Dutch firm Contronics 
Engineering. 
EUREKA ­ which plans to situate its 
action within the dynamic of the 
European Research Area ­ also 
welcomed two new members, the 
Federal Republic of Yugoslavia and 
Cyprus, bringing total membership 
to 33 European countries. Morocco 
was welcomed as an associate coun­
try. In regard to synergy with the 
Union, the highlight of the confer­
ence was the announcement of 
increased co­operation with the 
Innovation Relay Centres network, 
supported by the Commission. 
To find out more: 
www.eureka.be/ifs/files/ifs/jsp­bin/ 
eureka/ifs/jsps/publlcHome.jsp 
USA: scientific integrity in the firing line 
In 2001, the US Office for Scientific 
Integrity (ORI) investigated 127 cases 
of 'misconduct' by researchers: 46 
falsifications of results, 37 fraudulent 
scientific productions, 17 cases of 
plagiarism and 27 other cases of 
unacceptable behaviour of various 
kinds. These are the highest 'scien­
tific crime' figures recorded for five 
years. The ORI therefore decided to 
set up a committee consisting of 
members of the National Research 
Council and US Institute of Medicine 
to be charged with proposing strate­
gic recommendations to promote 
the concept of scientific integrity. In 
particular, the committee must draw 
the attention of the various research­
funding institutions and agencies to 
their responsibilities in encouraging 
a sense of ethics among researchers. 
When will we see a European ORI? 
To find out more: 
stills.nap.edu/books/0309084792/html/ 
Excellence: The French Fields Medal 
The most prestigious award in 
the field of mathematics 
the equivalent of the Nobel Í 
Prize ­ was awarded in 
2002 to Laurent Lafforgue, ^ 
36, a professor at the Institut des 
hautes études scientifiques, an institu­
tion which boasts five winners of the 
Fields Medal since 1958. Quoted in 
the French daily Le Monde, Lafforgue 
described Langlands Conjecture, the 
subject of his award­winning work, as 
'one of the most wonderful things 
ever proposed by mathemat­
ics. The statements are very 
simple and often run to no 
more than three lines. The 
fact that they can be true is 
simply staggering! But it takes 
several hundred pages to demon­
strate a number of very specific 
cases.' 
To find out more: 
Type 'Fields Medal' on the search engine 
www.google.com 
Erratum 
The article What is a university 
'worth'? ­ RTD info n° 34 
We mistakenly stated that 
the ALmaLaurea Consortium 
consisted of 19 universities. 
In fact it included 19 at the 
time of going to press and 
now numbers 30. 
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European notebook 
» Inauguration of the Sixth Framework 
Programme of the European Union -
Organised by The Polish State Committee 
for Scientific Research for the EU candidate 
countries -
25-26/11/2002 - Warsaw (PL) 
www.npk.gov.pl/konf-6PR/index_en.html 
» Towards sustainable agriculture for 
developing countries: options for life 
sciences and biotechnologies -
Organised by the European Group of Life 
Sciences-30-31/01/2003-
Brussels (BE) 
europa, eu. int/comm/research/conferences/ 
2003/sadc/index_fr.html 
Other events 
I PV for Europe - Conference and Exhibition on 
Photovoltaics Science - Technology and 
Application -
Organised jointly by 
ETA-Florence and WIP-Munich -
7-11/10/2002-Rome (IT) 
www.wip-munich.de/conferences/ 
pv/rome_02/index.html 
I 25th World Energy Engineering Congress -
9-11/10/2002 - Atlanta (USA) 
www.aeecenter.org/weec/ 
» EPIDOS Annual Conference 2002 -
The European Patent Office -
-17/10/2002 - Copenhagen (DK) 
www.european-patent-office.org/epidos/ 
conf/eac2002/home.htm 
» 2002 EVCA Technology Investment 
Conference -
16-18/10/2002 - Barcelona (ES) 
www.evca.com/html/events/ 
conferences_03.asp 
» SITEF 2002 -
International advanced technologies fair — 
23-26/10/2002 - Toulouse (FR) 
www.toulouse.cci.fr/ 
I European Conference on Aquatic Microbial 
Ecology (SAME 8) -
25-30/10/2002-Messina, 
Taormina (IT) 
www.same-8.it/ 
> Tenth ECMWF Workshop on the Use of High 
Performance Computing in Meteorology — 
4-8/11/2002 - Reading (UK) 
www.ecmwf.int/newsevents/workshops/ 
parallel2002/ 
» Rothamsted Biomarket Bioproduct from 
plants and Microbes -
5-7/11/2002 (UK) 
Biomarket@bbsrc.ac.uk 
> Baltic Biotech -
8-10/11 /2002 - Greifswald (DE) 
www.baltic-biotech.net 
ì Ecsite Annual Conference 2002 -
14-16/11 /2002 - London (UK) 
ecsite.ballou.be/net/beta.asp 
» International Chemical Information 
Conference & Exhibition -
20-23/10/2002 - Nîmes (FR) 
www.infonortics.com/chemical/index.html 
> Regards croisés sur les changements globaux 
Organised by the CNES and CNFCG -
25-29/11/2002-
Arles (FR) 
dag.distinguezvous.com/cnes/regards/ 
> EUREKA [meets] ASIA 2002 -
25-29/11/2002 - Macau (China) 
www.adi.pt/adl/default.asp 
I Colour of Ocean Data -
Organised by the Flanders Marine Institute 
-25-27/11/2002-
Brussels (BE) 
www.vliz.be/en/acruv/cod/ 
I Genomics and Forest Tree Stress Tolerance 
Short Course -
11/2002- Chania (GR) 
adoulis@maich.gr 
► Dynamics and Conservation of Genetic Diver­
sity in Forest Ecosystems -
2-5/12/2002 - Strasbourg (FR) 
www.pierroton.inra.fr/genetics/Dygen/ 
index.html 
» Annual Conference of the European 
Patent Office -
3/5/12/2002 - Nice (FR) 
www.epoline.org/epoline/nice/intro_en.htm 
I Awarding of the 2002 Descartes Prize -
5/12/2002-Munich (DE) 
www.cordis.lu/descartes 
» 7th international conference on public com­
munication of science and technology (PCST) 
network -
5-7/12/2002 - Cape Town (SA) 
www.pcstnetwork.org/ 
I Un pas vers l'Europe des chercheurs -
Launch of the EU's Sixth Framework Pro­
gramme for Research and Development -
Organised by the Swiss Federal Office for 
Education and Science - 6/12/2002 -
Berne (CH) 
www.konferenz6frp.ch/ 
» Biotech Helsinki -
24-26/3/2003 - (Fl) 
finnexpo.fi/biotechhelsinki 
I Nanotechnology Meets Business -
8-9/4/2003 - Frankfort (DE) 
www.nano.org.uk/nanomeets.htm 
I Telemedicine and Telecare 
International Trade Fair -
9-11/4/2003 - Luxembourg (LU) 
www.telemedicine.lu/ 
» The Biobiz workshops 
3-5/12/2002-Prague (CZ) 
21-23/1/2003-Berlin (DE) 
18-20/2/2003 - Paris (FR) 
18-20/3/2003 - Warsaw (PL) 
15-17/4/2003 - Hamburg (D) 
20-22/5/2003 - Vienna (AU) 
www.euroblobiz.com 
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Publications 
Project reports 
► Atlas historique des cadastres 
d'Europe (II) (Historical atlas of 
land use In Europe) — EUR-OP 
I Optical infrared coordination 
network for astronomy -
anna-maria.johansson@cec.eu.int 
» Surface energy balance in urban 
areas - EUR-OP 
I Bioactive compounds in plant foods 
- EUR-OP 
► Biogenically active amines in food -
EUR-OP 
» Apoptosis and programmed cell 
death : molecular mechanisms and 
applications in biotechnology and 
agriculture - EUR-OP 
I Plant biotechnology for the removal 
of organic pollutants and toxi 
metals from wastewaters and 
contaminated sites - EUR-OP 
► Brucellosis in animals and farm -
EUR-OP 
rtd-euratom@cec.eu.int 
► CLUSTER: Club of underground 
storage, testing and research facilities 
for radioactive waste disposal 
rtd-euratom@cec.eu.int 
I EU co-sponsored research on 
containment integrity 
rtd-euratom@cec.eu.int 
Printed publications accompanied 
by the mention of an e-mail address 
can be obtained by sending a 
message to the address given. 
EUR-OP (Office for Official Publica-
tions of the European Communities) 
means that the printed versions 
must be purchased. To order copies 
please visit the website at: 
eur-op.eu.int/general/en/s-ad.htm 
The publications mentioned are a 
selection. A complete list of scientific 
publications from the RTD 
programmes is placed on the 
research website every two months: 
europa, eu. ¡nt/comm/research/ 
pub_rtd.html 
Conference reports 
► Stem cells : therapies for the future? 
quality-of-life@cec.eu.int 
I Urban forest and trees -
http://eur-op.eu.int/general/ 
en/s-ad.htm 
> 8th and 11th Workshop of Marie 
Curie fellows: research training 
in progress -
wolfgang.kerner@cec.eu.int 
» FISA 2001 : EU research in reactor 
safety -
rtd-euratom@cec.eu.int 
Project catalogues 
I Measurements and testing & sup­
port for research infrastructures -
growth@cec.eu.int 
t Decision support for emergency 
management and environmental 
restoration -
ernst-hermann.schulte@cec.eu.int 
» Nuclear fission and radiation 
protection projects selected 
for funding 1999-2001 -
rtd-euratom@cec.eu.int 
Brochures and reports Leaflets 
t Talking science - A special edition 
of RTD Info on relations between 
science and the media -
research@cec.eu.int 
k National policies on women 
and science in Europe -
(see, article p. 38) 
brigitte.degen@cec.eu.int 
110 years of EC scientific coopera­
tion for the transition towards 
sustainability - (4 brochures) 
- Capitalising on people and 
institutions 
- Managed land ecosystems 
- Aquatic ecosystems 
- Healthy societies 
inco@cec.eu.int 
I European aeronautics : a vision for 
2020 - Meeting society's needs and 
winning global leadership — 
research@cec.eu.int 
k A research environment for an 
enlarged European Union 
► Targeting sustainable development 
around the Mediterranean Sea 
► Creating sustainable solutions in 
developing countries 
► Targeting sustainable development 
in Eastern and Central Europe 
inco@cec.eu.int 
Newsletters 
I Growth in action -
June St July 2002 
growth@cec.eu.int 
I SME Update - July 2002 
research-sme@cec.eu.lnt 
r Request for free subscription to RTD info 
You can subscribe free of charge to the magazine at 
http://europa.eu.int/comm/research/rtdinfo/rtd-adrf.html 
You can also complete this coupon in block capitals and return to the following address: 
RTD info 
MLDG1201 
Boîte postale 2201 
L-1022 Luxembourg 
Name: Organisation: 
Language version(s) desired*: 
French Q 
English Q 
German □ 
Address : 
Postcode: Town: Country: 
(*) If you would like to receive several copies of one language version, please make your request, giving your full 
name and a brief justification: 
- by e-mail (rtd-info@cec.eu.int) 
- by fax (+32-2-295 82 20). 
If you would like to receive a copy of any recent issues of RTD info, please send a brief message by e-mail or fax. 
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Useful Web addresses 
I Atlas of Oceans 
http://www.oceansatlas.com/ 
index, jsp 
On the occasion of last June's 
Environment Day, the FAO 
launched this site which provides 
a remarkable document base -
and which will continue to be 
enriched with all the latest 
knowledge in the field of the 
cartography, physics and ecology 
of all the world's oceans. 
t Antarctica on line 
http://www.antdiv.gov.au/ 
A valuable source of knowledge 
on the South Pole which is of 
the greatest interest to its closest 
neighbours, the Australians. 
I The eContent Village 
http://www.content-
village.org/default.asp 
The Platform for Information, 
communication and the sharing 
of knowledge on the latest 
developments in the eContent 
programme for the promotion of 
digital technologies and linguistic 
diversity in the information society. 
» Final text of the adoption 
of the Sixth Framework Programme 
http://europa.eu.int/comm/research 
/fp6/documents_en.html#(pdeclsions 
t Reference addresses for the latest 
information on the Sixth Framework 
Programme 
http://europa.eu.int/comm/research 
/fp6/index_en.html 
http://www.cordis.lu/fp6 
I Sites on the development 
of the European Research Area 
http://europa.eu.int/comm/research 
/era/index_en.html 
http://www.cordls.lu/rtd2002/ 
Recent news on the 
EUROPA RESEARCH 
server 
► Women & Science: Statistics and 
Indicators - All the figures on 
'research and gender' 
http://europa.eu.int/comm/ 
research/science-society/women/ 
wssi/index_en.html 
► EU funded TSE research in Europe 
Research on BSE or mad cow 
disease 
http://europa.eu.int/comm/research/ 
quallty-of-life/tse/index_en.html 
I EU-fundcd Agricultural Research 
Portal 
http://europa.eu.int/comm/ 
research/agr¡culture/lndex_en.html 
I Animal Welfare - Alternatives 
to animal experimentation 
http://europa.eu.lnt/comm/ 
research/quality-of-life/animal-
welfare/seminars/index_en.html 
I Communicating science 
Research and citizens 
http://europa.eu.int/comm/ 
research/science-society/ 
sciencecommunlcatlon/ 
links_en.html 
► Science and technology indicators 
for the ERA 
The performances of European 
Research 
http://europa.eu.int/comm/ 
research/era/sti_en .html 
Recent news on 
the CORDIS site 
» Quality of Life Bulletin, July 2002 -
Newsletter of European research 
in the life sciences 
http://www.cordis. lu/life/src/ 
news0800.htm 
I Nanotechnology -
A new priority of the Sixth 
Framework Programme 
http://www.cordis.lu/ 
nanotechnology/ 
t Research in Finland sur Cordis -
In the European Research Area 
series of sites 
http://www.cordis.lu/finland 
I Cordis library -
New access service to documents 
and publications on research 
and innovation published in the 
context of European programmes 
http://www.cordis.lu/library 
» Cordis NCP Network -
Access to all national contact 
points able to Inform you on 
RTD In the EU Member States 
and associate and candidate 
countries. 
http://www.cordis.lu/fp5/ 
src/ncps.htm 
t CORDIS Regional Research and 
Innovation -
the portal of the regions of 
the European Research Area 
http://www.cordis.lu/regions/ 
Access to all issues of RTD info at the Europa/Research site/ 
(html or PDF version) 
French: http://europa.eu.inf/comm/research/rtdinfoJr.html 
English: http://europa.eu.int/comm/research/rtdinfo_en.html 
German: http://europa.eu.int/comm/research/rtdinfo_de.html 
Spanish* : http://europa.eu.int/comm/research/rtdinfo_es.html 
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Far 
from 
Belgium, Germany, France, Italy, Luxembourg and the Nether-
lands signed the treaty establishing the ECSC in Paris on 
18 April 1951. It was the practical follow-up to the declara-
tion C) by French Foreign Minister Robert Schumann on 9 May 
1950 that proposed placing Franco-German production of coal 
and steel under a common High Authority within the frame-
work of an organisation open to participation by other Euro-
pean countries. This first European Community set out to put an 
end to a century of national rivalries by a peaceful reconstruction 
based on shared interests. It was also an institutional test bed 
from which several years later developed the more ambitious 
Treaty of Rome establishing the Common Market. 
The end of the European Coal and Steel Community 
(ECSC) Treaty does not signify that a technological era 
is over either at the European or global level. Coal and 
steel will continue to play major roles in the areas of 
energy and basic materials for many years to come. 
Keen to conserve the dynamic role of Community 
innovation, which had kept European know-how at 
the forefront of both sectors, the Member States 
decided to use all the residual funds from the treaty 
to continue specific research in these key areas. 
finished 
Research-based strategy 
Over the next five decades, the ECSC played a major economic 
role which extended far beyond these two industries. Coal and 
steel were important elements in rebuilding Europe immediately 
after the war and through the 1950s and 1960s, but the subse-
quent major decline in demand for both could have plunged 
Western Europe into a dangerous economic recession. The 
ECSC functioned smoothly in striking the right balance by 
improving productivity and by developing products to support 
new industries. An essential characteristic of the ECSC was the 
considerable means dedicated to research. 
Subsequently, the ECSC helped to develop an organised 
response when the coal and steel industries went into deep crisis 
in the 1970s and 1980s. This made it possible to carry out the 
necessary industrial restructuring and conversion while placing 
particular emphasis on the protection of workers' rights, in 
keeping with the European social model. 
A key component of the ERA 
The 23 July 2002 marked a definitive step in EU history as the 
50-year-old treaty expired. After that date, all remaining avail-
able ECSC funds - some €1.6 billion - would normally have 
reverted to the Member States. However, the innovative spirit 
that helped develop the ECSC research programme as a very 
strong element of the European Research Area led to the Council 
agreeing to continue common funding of RTD in these two 
sectors. Under the management of the European Commission, 
that decision will provide some €45 million a year which will 
© Avesta Polarit 
cover activities not included in the Sixth Framework Programme. 
The funding will be split into 27.2% for coal-related research 
and 72.8% for steel-related research. 
Coal offers an indispensable source of energy in the context 
of the overall European strategy for the security of its energy 
supply. But, even if research has enabled considerable progress, 
the challenge still remains to make it cleaner and to reduce 
emissions of CO2 that contribute to the greenhouse effect. 
The production of steel is closely linked to coal and shares 
the challenges. However, it has now established itself as a flex-
ible, high-technology material adding value to a wide range of 
applications. The Commission will manage future research in 
both areas with even greater emphasis on the environmental 
objectives. O 
(1 ) http://europa.eu.int/abc/symbols/9-may/decl_en.htm 
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The quest for clean 
Safety, energy efficiency, the f ight against pol lut ion... Decades of research 
under the auspices of the ECSC have resulted in a European know­how in 
the coal industry unequalled anywhere in the wor ld. In the Union's strategy 
for energy independence over the coming decades, 'clean coal' is set to be 
a valuable asset. 
Solid fuels 
The Carnot Programme, launched in 
December 1998 and set lo terminate 
at the end ol this year, has been 
mainly concerned with the development 
ot clean and efficient technologies lor 
the combined combustion of coal with 
oilier solid fuels, such as lignite, 
peat, oil shale, the heavy dérivâtes of 
petroleum products, and biomass. 
As well as environmental issues and 
questions of efficiency, the Carnot 
Programme has also looked at the 
related technical and economic 
aspects of solid fuels, such as 
preparatory processing, storage, 
transport and waste disposal. 
An enlarged 
European coal area 
Union enlargement will bring a 
considerable increase in coal reserves 
and its use as a European energy 
source. II will also bring an added 
environmental burden which requires 
urgent action. In 1998, when Union 
production was estimated at 
158 million tee, the six candidate 
countries with coal reserves ­
principally Poland and the Czech 
Republic, and to a lesser degree 
Hungary, Bulgaria, Romania and 
Slovakia ­ produced a total of 
167 million Ice. Coal provides 65% 
ol the electricity produced in 
the luture Union members as a whole, 
compared with just 27% in 
the present 15 Member States. 
The ECSC Treaty is ending on a paradox. Over the last 
three decades its ­ successful ­ mission has been to man­
age the decline in the Union's coal product ion, linked to 
the deplet ion of resources and g row ing diff icult ies of 
access to the European subsoil. 
EU coal product ion fell f rom 200 mil l ion to 85 mil l ion 
tonnes between 1989 and 2000. Today, just four produc­
ing countries remain: Germany and the United Kingdom, 
and to a lesser degree Spain and France. Lignite production 
is also down, wi th Germany the biggest remaining pro­
ducer, followed by Greece and, some way behind, Spain. 
With 240 million tonnes produced in 2000, lignite repre­
sents about 50 million tonnes of coal equivalent or 'tee'.ζ1) 
Timely excellence 
At the same t ime, by virtue of its research programmes, 
the ECSC Treaty has brought continuous technological 
improvements in min ing safety and yield, energy effi­
ciency and clean combust ion. 'Europe leads the wor ld 
when it comes to coal industry know­how, ' stresses Chris­
t ian Cleut inx, d i rector of convent ional energy at the 
Commission's Energy and Transport Directorate­General. 
This h igh level of excellence is a major advantage in 
the 21st century economy. First of all, because coal 
remains an energy source of primary importance, not 
on ly at the g lobal level ­ coal meets one­quar ter of 
world's energy needs ­ but for Europe too. A l though the 
Union is p roduc ing less and less coal, it cont inues to 
consume a great deal . In 2000 it impo r ted almost 
160 000 mil l ion tonnes of coal, mainly to meet its ther­
mal electricity product ion needs. 
Also, the Union of 15 Member States is about to enlarge 
to include countries which are major coal producers and 
consumers ­ countries which are also facing problems of 
modernising, restructuring and scaling down their mining 
industries as well as improving their combustion plants. As 
stressed in the Green Paper Towards a European strategy 
for the security of energy supplies, published by the Com­
mission in 2000, far f rom being an energy source of the 
past, coal is set to be of great strategic importance in elec­
tricity production over the coming decades. 
'It is a fuel which is in abundant supply in many regions 
of the wor ld , ' stresses Christian Cleutinx. 'The OECD esti­
mates there are reserves of around 1 000 mil l ion tonnes, 
representing 200 years of wor ld consumpt ion at present 
rates. Unlike hydrocarbons, the many supply sites in 
themselves constitute a guarantee of stable prices and 
secure supplies.' In technical and economic terms, coal is 
particularly interesting when used as a combined fuel 
w i th other solid fuels of less value (such as lignite and 
peat), heavy hydrocarbon dérivâtes and biomass. 
The use of these inexpensive energy sources must, how­
ever, respect one fundamental condi t ion: respect for the 
environment. As a major source of SO2, NO* and CO2 ­
emissions, and thus seen as a major factor in cl imate 
warming, coal ­ and other solid fuels w i th which it may 
be combined ­ must be the subject of a major research 
and innovat ion effort if it is to qualify as a clean fuel. 
ECSC achievements 
This is a chal lenge wh ich can be met and ECSC 
researchers have already laid down the foundations for 
doing so. Major technological advances have been made 
in two areas: PFBC or pressurised fluidised bed combined 
cycles and, most recently, integrated gasification com­
bined cycle or IGCC.(2) 
The Gardanne power station in France uses 
the clean technology of combined cycle 
combustion on fluidised beds. 
©EDF 
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coal 
Other research projects are also concerned w i t h the 
concept of 'clean coal ' , in particular in the area of f i l ter-
ing and recycl ing systems for harmfu l a tmospher ic 
emissions, the 'sequestrat ion' of C 0 2 emissions, and the 
co-combust ion of solid fuels. 
'If we want this fuel to play its strategic role in terms of 
energy security, then it must meet the increasingly 
demanding environmental challenges posed by climate 
warm ing , ' stresses Andrew Minchener, member of the 
ECSC's commit tee of experts on combust ion and gasifi-
cat ion. 'If it is to retain its present leadership role in this 
technological sector, research on advanced combust ion 
cycles must cont inue, in particular on the particularly 
efficient opt ion of gasification.' Q 
(1) Tonne of coal equivalent is one tonne of high-quality coal 
possessing a standard calorific value of 7 000 Kcal/kg. 
(2) PFBC: Pressurised fluidised bed combined cycle - IGCC: 
Integrated gasification combined cycle. 
Two advanced 
technologies 
The PFBC process involves feeding a current of air 
under pressure (12-16 bars) into a combustion chamber 
heated to 850°C, thereby creating turbulence in a bed 
of inert particles and cinders which starts to behave 
like a fluid. The coal is introduced into this fluidised 
bed, where it is burned with a calcium-based sorbent 
(such as lime). About 80% of the electrical energy gen-
erated by this combustion is obtained by circulating 
water through tubes located in the fluidised bed which 
fuel a conventional steam turbine. The gases emitted 
by the combustion are then cleaned and sent to a gas 
turbine which generates additional electricity, permit-
ting a high thermal yield of around 44%. 
In the IGCC process, the gasified coal fuels a Brayton 
cycle gas turbine, which is a particularly efficient 
system of electricity generation with low emission levels. 
Gasification provides up to 90% enhancement of the 
coal's calorific capacity. This process also includes 
added electricity production through heat recovery by 
means of steam production fuelling a second turbine. 
Contact 
OChristian Cleutinx 
Iransport and Energy DG 
christian.cleutinx@cec.eu.int 
To find out more 
OCoal research at the Iransport 
and Energy DG 
europa.eu.int/comm/energy/ 
en/la„13_en.html 
OCarnot Programme 
europa.eu.int/comm/energy/ 
en/pts _carnot_en.html 
OConclusions ol the Commission's 
Green Paper on Energy 
http://europa.eu.int/comm/ 
energy transport/Iivrevert/final/ 
report_en.pdf 
Hi 
:^i A''Mi 
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Steel has a tough life 
Contacts 
O Luisa Prista and Joachim Ball 
Research DG 
luisa. pristaOcec. eu. int 
Joachim.ballQcec.eu.int 
Despite competi t ion f rom new materials, 
steel - or perhaps more accurately 'steels', 
given the many forms developed to meet 
different requirements - is and will remain 
an essential component of our technological 
environment. Thanks to constant efforts to 
adapt and innovate wi thin the ECSC, Europe 
is a world leader on today's steel market. 
This enviable position requires a continuation 
of the research effort made over past decades. 
The Union produces more than 60 mill ion tonnes of raw 
steel every year, or 2 0 % of wor ld product ion. Faced w i th 
increasingly keen international compet i t ion, over the past 
three decades this key sector has experienced a wave of 
restructuring and concentrat ion, coupled w i th techno-
logical modernisation on a large scale. 
New jobs and technology 
The European steel industry currently employs 277 000 
workers. In 1 952, when the ECSC was created, the six 
Common Market countries employed half a mil l ion steel-
workers, producing 40 mill ion tonnes of steel. In 1973, 
when the sector began to experience a crisis, the steel 
industry employed 774 000 workers producing 10 mil-
lion tonnes below the present figure. 
The ECSC played a vital role in the essential process of 
change in the steel industry, in two respects. At the social 
level, Commun i t y efforts to provide retraining meant 
little unemployment among former steelworkers. At the 
technological level, support for research was a key cata-
lyst in permi t t ing the modernisation of the whole pro-
duct ion line and satisfying environmental demands. 
Pioneering 
'The ECSC played a pioneering role that foreshadowed 
the concept of the European Research Area by opt ing for 
integration, which enabled three generations of scientists 
and engineers to learn to work and innovate together, ' 
stressed European Commissioner Phil ippe Busquin last 
June at a conference which took stock of progress in the 
steel sector to date and looked ahead to future steel 
research. 
The ECSC programmes enabled the steel industry t o 
increase the essential jo int effort for technological inno-
vation in areas such as product diversif ication, process 
a u t o m a t i o n , i m p r o v e m e n t in w o r k i n g cond i t i ons , 
reduction of pol lut ion and energy savings. 
This continuous research drive, costing almost a bil l ion 
euro (funded by a minimal charge on each tonne pro-
duced) produced results which all those involved agree 
were beneficial. A 1995 study showed that every euro the 
ECSC invested in research projects generated about a 
dozen euro in return. Q 
To find out more 
OSile of the new Steel programme 
www.cordis.lu/ 
coal-steel-rtd/sleel/home.html 
OSile ol lhe Growth programme 
europa.eu.int/comm/research/ 
growtli/gcc/ga02.htmlStop 
'Post-ECSC' research 
Adopted last February, the Union's new 2002-2006 'steel' programme will continue the European drive for techno-
logical innovation in parallel with the start of the Sixth Framework Programme. (') The shared research priorities lie 
in two main areas: 
• continued innovation at every stage of the production line with a view to sustainable growth (reduced emissions, 
energy savings, recycling and rational use of primary resources), increased competitiveness and improved product 
quality; 
• the development of new market opportunities by producing special steels with very high-level performances in 
terms of their properties (at extreme temperatures, corrosion resistance, antiseismic characteristics, etc.). 
(Z) Details of the organisation of this new programme can be consulted on the CORDIS server (www.cordis.lu/coal-steel-rtd/steel/home.html). 
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A marriage of increased 
productivity and 
environmental improvements 
Images of the large steel-making centres of 
the last century, shrouded in a thick black 
pall of toxic smoke, probably remain as 
the strongest symbol of industrial pol lut ion. 
The accumulated technological progress of 
many years of research and innovation has 
since made such scenes obsolete. 
This radical change was not, however, the result of a dra-
matic ' revolut ion ' in the basic thermodynamic principles 
used in the process of transforming iron into steel. For 
50 years the ECSC's pol icy was to suppor t research 
br inging many 'small ' innovations. This patient policy of 
advanc ing in measured steps, compr is ing projects 
addressing both product iv i ty and purely environmental 
aspects, produced very signif icant global results. 
The optimal operation of modern blast furnaces involves a 
real-time analysis of a variety of data which goes far beyond 
what man could do. Cognitive information systems now 
permit a unified approach to collecting and interpreting 
data within the alloy production unit, and bring decisive 
improvements to a centuries-old technology. Pictured here is 
the steel control room at the Avesta Polarit plant in Sweden. 
©Avesta Polarit 
The durability 
of steel 
Steel is not only the world's most 
used metal material, it is also the 
most recyclable and recycled. 
In terms of natural resources this 
economy is also an economy in itself: 
production by recycling is less 
expensive and consumes less energy 
than smelting steel from minerals. 
About 45% of steel products in 
current use are made from recycled 
ferrous waste, a percentage that is 
growing all the time. 
COz cut by half 
Progress made in control l ing the quality of the blast fur-
nace charge, the use of combined fuels and equipment 
improvements means that today one tonne of steel can 
be produced using 450 kg of coke equivalent compared 
w i th 900 kg in the 1 960s. Al though the initial aim of such 
energy savings was to reduce product ion costs, it has also 
resulted in a 5 0 % reduction in CO2 emissions. 
Another recent example is the spectacular progress made 
in the development of continuous smelting processes for 
stainless steel and thin strip carbon steel which drastically 
reduces the t radi t ional steel-rol l ing activities and the 
associated energy and equipment costs. 
The zero waste objective 
Since the late 1980s, at the same t ime as cont inu ing 
efforts to boost productivity and reduce energy consump-
t ion, the ESCE's Steel research programme has concen-
trated increasingly on projects directly related to strictly 
env i ronmenta l concerns. Many projects have been 
financed in the field of the agglomerat ing process which 
is responsible for one- th i rd of the dust emissions and 
two-thirds of the SO2 emissions of the steel industry as a 
who le . This research has focused on innovat ions to 
provide fi l tering systems that are more effective than the 
convent ional electrostatic processes, the reduct ion of 
emissions at source, and the model l ing of parameters 
involved in the manufacturing processes which are the 
cause of harmful emissions. 
Another key field is the processing and recycling of all the 
toxic waste and by-products of the steel industry, as well 
as waste water treatment. O 
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The secret of matter 
Electroweak interactions - which 
physicists have been racking their 
brains trying to explain lor decades 
and which were elucidated mathe­
matically by the't Hoofl-Veltman 
theoretical model - are essential to 
an understanding of matter and, 
what is more, to the chemistry of a 
star such as the Sun. II it were not 
tor electromagnetic interactions, 
electrons would not revolve around 
the nucleus a nd there would be no 
atoms. II is weak interactions which 
convert protons into neutrons and 
cause lhe lusion ol hydrogen atoms 
to form a helium nucleus in the great 
solar cauldron without which our 
planet Earth would be no more lha n 
an uninhabited ball of ice. 
Internet site 
Ohttp7/www.phys.uu.nl/-thoott/ 
See also 
Owww.nobel.se/physics/ 
laureates/1999/illpres/index.html 
Contact 
OGerard 't Hoott 
g.lhootl@phys.uii.nl 
The beauty 
of theory 
Gerard 't Hoof t : 'Most of the ills of the wor ld do not come f rom 
knowledge but f rom human behaviour. And it is only through 
knowledge that this behaviour can evolve.' 
The lineage of this learned Dutchman reveals a qui te 
remarkable concent ra t ion of scientif ic excel lence. His 
great uncle on his mother 's side, Frits Zernike (1988-
1966) , received the Nobel Prize in Physics in 1953 -
when Gerard was seven - for inventing the phase-con­
trast microscope, a revolutionary tool for the study of 
biology. His grandmother had married Pieter Nicolaas 
van Kempen, the eminent zoologist and professor at the 
University of Leiden, and one of their sons (thus Gerard's 
maternal uncle), Nicolaas Godfr ied, taught theoret ical 
physics at the University of Utrecht. 
It was hardly surprising therefore that Gerard dreamed of 
becoming 'a great man who knew everything' , and f rom 
a very early age he showed a fascination for observing the 
wor ld and nature around h im. A wor ld-renowned physi­
cist now, he continues to add to his collection of seashells 
which he began as a boy when walking the beaches of 
the Netherlands - because 'a seashell expresses the inex­
haustible beauty of matter worked by life'. 
A fascination with discovery 
His father, a bri l l iant naval engineer, had fo r a whi le 
thought of interesting his son in the very palpable wor ld 
of technological innovat ion. But that failed to allow for 
the inheritance f rom his mother's side of the family. What 
really fascinated the schoolboy - and later the student -
were not ' th ings already invented but the mystery of 
those to be discovered'. At secondary school, Gerard ' t 
Hooft was good at most subjects, but he excel led in 
mathematics. At the age of 16 he won second prize in 
the national 'Maths Olympiad ' . When the t ime came to 
go to university, this talent for dealing w i th the abstract 
caused him to opt for physics. He enrolled at the University 
of Utrecht where his uncle was a lecturer. 
It was there, in 1969, that he started working under the 
direction of Martinus Veltman, his mentor and elder by 
15 years w i th w h o m , 30 years later in 1999, he wou ld 
share his Nobel Prize. It was Vel tman w h o introduced 
him to the fascinating challenges of quan tum physics. 
'This was a very excit ing t ime as we were starting to use 
the first large particle accelerators, at CERN for example, 
which had been developed in the 1950s. These instru­
ments of exper imenta t ion radical ly changed exist ing 
theories formulated to describe the co-existence of forces 
of strong and weak interaction between the particles of 
the a tomic nucleus. The results observed rendered 
obsolete the methods of calculat ion proposed by the 
theories. At the same t ime, calculating capacity increased 
enormously wi th the first big computers. ' 
Electroweak interactions 
Veltman, who believed in the possibility of a new theory 
on what physicists call electroweak interactions (see box), 
set about pioneering a software program able to handle 
the previously indigestible mass of quantum calculations 
required by this new approach. He suggested to the 
young Gerard ' t Hooft tha t this theoret ica l research 
should be the subject of his doctoral thesis. His conf i ­
dence in his assistant proved to be well placed. In 1971 , 
at the age of 26, ' t Hooft published two articles in quick 
succession which constituted a new and decisive theoret­
ical approach to electroweak interactions. Wi th the aid of 
Veltman's software program the two researchers pro­
ceeded to ver i fy the part ial results and then j o in t l y 
deve loped a comp le te func t iona l ca lcu la t ion whose 
validity as a theoretical edifice has since been increas­
ingly conf i rmed. 
Their work was used extensively, for example, in the con­
trolled experiments on the product ion and identif ication 
of W and Ζ subatomic particles by CERN's LEP accelera­
tor. The Veltman-'t Hooft model is also at the origin of 
predict ions of the existence of an as yet unident i f ied 
particle, the famous 'Higgs boson', something of a 'Holy 
Grail ' for contemporary physicists. 
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'Is it the environment I grew up in or my genes which determined my vocation as a physicist?' 
That is the question Gerard 't Hooft asks in an autobiographical paper wr i t ten when he was 
nominated for the Nobel Prize in Physics in 1999. RTD info profiles a man of science wi th a 
distinct sense of humour. 
Communicating curiosity 
Gerard 't Hooft does not, however, share the passion of some 
scientific experimenters who scrutinise the 'soup' of particles 
turning in the accelerator. 'I have of course spent many working 
visits at CERN, but my passion is the beauty of theory. I am at 
present studying the absolutely fascinating concept of quantum 
black holes in the field of astrophysics.' 
Remaining loyal to his old university in Utrecht, this 1999 
Nobel prizewinner divides his time between pure research and 
lecturing on theoretical physics. 'For me it is very important 
not so much to transmit knowledge as such but to have a pas-
sion for curiosity.' As we speak, a new generation of doctorate 
students are hard at work in the neighbouring rooms, the 
blackboards full of equations. In fact, 't Hooft was a member of 
the jury for the last Young Scientists Competition organised by 
the Commission. 
Has the study of science retained the ¡mage it had during his 
young days? 'No. Relations between science and society - and 
young people in particular - have become problematic. As a 
boy and then adolescent growing up in the 1950s, I knew a 
world in which the researcher and his work, in all its arduous-
ness, had a genuine aura. Today we are living in a world where 
the importance of comfort leaves less room for effort. There is a 
danger of real scientific illiteracy, which is also the reason for a 
deplorable and absurd tendency to mistrust science. Most of 
the ills of the world do not come from knowledge but from 
human behaviour. And it is only through knowledge that this 
behaviour can evolve.' 
Humour and the web 
A physicist sensitive to communication matters, Gerard 't Hooft 
is also a man with a sense of humour - that much is clear from 
his website. (') Naturally he speaks of his interest in black holes -
and directs you to a US site where you can find the answers to 
all your questions on a subject which never fails to fascinate. An 
African lion sprawled in the shade of a tree then invites you to 
discover some remarkable photos taken by Gerard in Zimbabwe 
during the eclipse of the sun in June 2001. 
(1) Titt pî7/ ww w.p hys.uu.nl/~thooft/black_h.html 
He is also passionately interested in space and the many 
promises it holds. There is in fact an asteroid named 9491 
Thooft, discovered in 1971 by a couple of Dutch astronomers 
working at the Palomar Observatory in California. Visitors to the 
NASA website can study its spatial orbit which takes it between 
Mars and Jupiter. Thooft, which even has a draft constitution 
comprising 1 3 articles, is also the neighbour of the asteroid B 
162 inhabited it seems by a certain Little Prince... 
Other links take you to a plan to build a hotel on the Moon and 
a campaign for a permanent human presence on our satellite 
which has been abandoned for the past 30 years. 'I believe that 
sooner or later the adventure of manned flights will resume and 
that we will ultimately explore our solar system.' But make no 
mistake - there is no straying from the strictly scientific, and 
't Hooft has no time for the charlatans who try to distort the 
principles of physical rationality to justify paranormal fantasies. 
Finally, the 't Hooft site pays homage to the peculiarity of 
names which strangely begin with a back-to-front apostrophe 
followed by a small t. A letter which, in their wisdom, word 
processing programs are incapable of respecting when it comes 
to drawing up an alphabetical list. 'My name often appears 
right at the beginning, or right at the end, before Mr Aaron or 
after Mr Zzzwylitski, who thought their place was assured.' O 
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Aids, malaria, tuberculosis: 
Sub-Saharan Africa is plunging ever deeper into a deadly spiral. Poverty engenders disease which 
in turn generates more poverty. In partnership wi th scientists and health officials in the countries 
affected, the European Union is launching a major clinical research project to halt the progress of 
the three transmissible diseases which are draining this sub-continent of its l ifeblood. 
Health threats to the world's poorest countries, which lock 
them into a vicious circle of underdevelopment, are reaching 
the limits of endurance. The international community officially 
recognised the seriousness of the situation three years ago. 
Meeting in Okinawa in July 2000, the G8 countries agreed on 
the need 'to step up the fight against poverty in the developing 
countries' and to implement 'urgent measures to combat infec-
tious and parasitic diseases'. 
Field trials 
In September of the same year, the European Commission pro-
posed a new political framework to 'accelerate the fight against 
the principal transmissible diseases in the context of poverty 
reduction' and, in partnership with the WHO and the UNAIDS 
programme, organised broader consultation with many of the 
countries concerned, international development agencies, the 
world of research and the pharmaceutical industry. In April 
2001, the first HAD (Health, Aids, Demography) action took 
practical shape, aimed in particular at strengthening pharma-
ceutical policies, stepping up the research effort and boosting 
international partnerships. 
Last April, this new commitment gave rise to the launch in 
Barcelona of the European and Developing Countries Clinical 
Trials Partnership on Poverty-related diseases (EDCTP). This 
aims to develop clinical trials for new treatments and vaccines 
against Aids, tuberculosis and malaria in sub-Saharan Africa. 
'Increased and more effectively coordinated clinical research is a 
prerequisite for pushing back the tide of destruction caused by 
these diseases,' stresses Antoni Trilla of Barcelona University's 
Hospital Clinic, coordinator of the project's start-up phase. 
'Each of them takes a different form and poses its own problems 
of diagnosis, treatment and prevention which are also linked to 
specific local conditions, both geographic and social.' 
An increasingly alarming health situation 
Poverty-related diseases are not exclusive to sub-Saharan Africa. But the death toll in this region is assuming catastrophic propor-
tions, currently estimated at nearly 5 million a year. 
The latest UNAIDS(') figures show that, of an estimated 40 million people carrying the HIV virus worldwide, 28.5 million inhabit 
this subcontinent. Every year in Africa, Aids kills 2 million people, a sixth of them children. There are also 14 million orphans in 
Africa whose young parents have died of Aids. 
Tuberculosis affects 1.5 million people in sub-Saharan Africa and its spread is clearly closely linked to the spread of HIV/Aids. This 
contagious disease, of global dimensions and now on the increase, causes 2 million deaths a year. 
Finally, the return of malaria is mainly affecting Black Africa, with more than 400 million suffering from the disease and almost a 
million deaths a year. 
This devastation of the population - and its cost in terms of health care and the loss of individuals able to contribute to society -
constitutes a genuine brake on development. The growing cost of disease is to the detriment of resources available for education. 
The circle is all the more vicious as it is education more than anything else which holds the key to ending the misery and improving 
health. In its alarming report, the United Nations stated that the overwhelming majority of young people are unaware of how Aids 
is transmitted and how to protect themselves against it. 
(/) Highlighted at the HIV/AIIDS conference in Barcelona last ¡uly. 
RTD info N° 35 October 2 00 2 35 
an urqent clinic 
m 
counter-attack 
in Africa 
To find out more 
OPresentation of the EDC1P project 
europa.eu.int/comm/research/inlo/ 
conferences/edctp/edctp_en.html 
OCommission action programme 
Accelerated action in the light 
against HIV/AIDS, malaria and 
tuberculosis in the context of 
poverty reduction 
europa, eu. int/conim/developnient/ 
document/com_en.fitm 
Olnfnimation on Aids 
www.unaids.org/ 
Olnformation on tuberculosis 
www.who.int/tdr/diseases/ 
tb/default.htm 
www.hophins-tb.org 
Olnformation on malaria 
www.who.int/tdr/diseases/ 
malaria/default.htm 
www.who.int/inl-ls/en/am203.html 
www.malaria.org/ 
IV l l . l t l ' .M I . l l . l l l . l l l l l l l l 
The genetic diversity of the HIV virus in Africa poses a 
major problem and requires solutions adapted to the 
continent. On the left, the HIV- 7 virus which is responsible 
for Aids and on the right the nucleocapsid containing the 
genome and enzymes. 
© INSERM 
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Contact 
OAntoni [rilla, Hospital Clinico 
University of Barcelona (ES) 
atrilla@clinic.ub.es 
OStephane Hogan, Research DG 
slepliane.hogan@cec.eu.int 
African delegation 
lhe EDCIP met with a very favourable 
response in Africa, as illustrated by 
the presence of key political figures at 
the conlercnce to launch the project, 
last April in Barcelona, lhe African 
delegation included Mozambique's 
Prime Minister Pascoal Mocumbi 
together with the country's senior 
public health official Richard 
Thompson, Cameroon Health Minister 
Awa Coll-Seck, and many leading 
scientific experts recognised by 
international organisations, such 
as I red Binka and Francis Nkriimah 
(School ol Public Health, University 
of Ghana), Wen Kilarna and Hassan 
Mshinda (African Malaria Network 
trust and llakara Research Centre, 
Tanzania), Solomon Benatar (Univer-
sity ol Cape Town, South Alrica), 
Ornou Y Sow (Conakry, Guinea), 
Soulcymane M'Boup (Hôpital Le 
Dantec, Senegal) and Leopold Zekeng 
(Cameroon). 
These leading scientists, together 
with Trancine N'Toumi (Gabon), and 
Voahangy Rasolofo (Madagascar), 
constitute the 'coordinating group of 
Southern countries' within lhe TDCÍP 
which is working in partnership with 
European scientists. 
A la carte research 
One example is Plasmodium falciparum, wh ich is wreaking 
havoc across whole swathes of sub-Saharan Africa. This 
agent is at the or igin of a very severe form of malaria 
made all the more serious as populations are showing an 
increased resistance to known anti-malaria drugs, result-
ing in an increasingly high mortal i ty among new-borns 
and pregnant women. New treatment combinat ions and 
possible vaccines must therefore be tested, whi le at the 
same t ime developing new preventive measures based 
on insecticides. 
In the case of Aids, the genetic diversity of the HIV virus 
found in Africa poses a major problem. The use of com-
plex forms of preventive or therapeutic vaccines which 
are the subject of intense research in developed countries 
is not a realistic prospect in the African context. There 
must be research and clinical trials on forms of preven-
t ion/treatment/vaccinat ion adapted to the capacities for 
the supply and consumpt ion of health care in the poor 
countries. 
Finally, new medicines - and the research to develop them 
- are needed to combat the resurgence of tuberculosis, 
now present in a part icular ly acute and resistant f o r m . 
Public aid 
Vital clinical research is most certainly the heaviest initial 
i tem of investment in developing new vaccines and treat-
ments adapted to the socio-economic contex t of the 
Southern Hemisphere. ' I t is essential for t he publ ic 
authorit ies to init iate this process as at this stage the 
pharmaceutical industry is clearly reluctant t o commi t 
itself alone given the lack of a guaranteed return on the 
investment , ' stressed Commissioner Phil ippe Busquin 
in Barcelona. 
This public commi tment has largely taken shape already. 
'The EDCTP is not being set up in abstracto,' points out 
Michèle Boccoz of the Institut Pasteur (FR), member of 
the initiative's Management Group. The project aims to 
federate the various approaches already adop ted by 
clinical research in sub-Saharan Africa. These are being 
pursued by the WHO and UNAIDS as part of bilateral or 
multilateral initiatives supported by various countries or 
foundations, or by European programmes. 
The EDCTP's aim is to provide a coherent response which 
draws on Communi ty and national efforts. Such an open 
and concrete approach reflects the phi losophy of the 
European Research Area. This project can in fact be seen 
as a kind of advance 'pi lot test' of the 'new instrument of 
Article 1 69' which wil l enter into force under the 2002-
2006 Framework Programme. 
This provision enables the Commission to fund research 
and development projects carried out by Member States 
and associated countries (15 EU countries plus Norway in 
this specific case). The Communi ty is contr ibut ing € 2 0 0 
mil l ion to implement ing the EDCTP initiative. Addit ional 
resources wi l l come f r o m funds invested in nat ional 
p rog rammes and f r o m in te rna t iona l o rgan isa t ions , 
whether publ ic or private, wh ich decide to help f inance 
clinical trials. 
Creating a translational dynamic 
'In addition to networking all those involved in the project, 
w h i c h f r o m the outset plans to act ively invo lve the 
biopharmaceutical industry, the EDCTP wants to encour-
age new avenues of research, in par t icu lar t h r o u g h 
progress in genomics and proteomics. It is a matter of 
accelerating the " t rans la t ional " dynamic between the 
most recent knowledge and its appl icat ions, ' explains 
Antoni Tril la. 
The financial resources provided by the Union wil l make 
it possible to support p i lot test sites wh ich may be pro-
posed at European level or by African health officials. 
W i t h i n a vast co-opera t ive ne twork , these sites w i l l 
ensure the synergy and convergence of research -
wh ich , at present, is too disseminated or isolated - w i t h 
the aim of jo int enhancement and emulat ion. The aim is 
to develop new and appropr iate treatments wh ich are 
easy to use and inexpensive. The project also wants to 
encourage the coherency of initiatives in the f ie ld, by 
providing a reference for the val idat ion of the results of 
clinical trials which is applicable to the medical samples 
and the patients treated. 
Essential North-South partnership 
Finally, a crucial foundat ion for the EDCTP is to create a 
long-term and clearly affirmed partnership w i th African 
scientists and health officials w h o are current ly in the 
f ront line of the f ight against the three pandemic dis-
eases. Antoni Trilla believes that ' the know-how, knowl-
edge and experience of the Africans work ing in the field 
is indispensable. It wou ld be unthinkable - and impossible 
- to conduct clinical trials w i thou t recourse to these able 
local players w h o are in direct contact w i th the affected 
populat ions. This partnership is, moreover, central to 
the current task of ident i fy ing the geographica l and 
social sites of a size and nature to be validly used for 
clinical trials.' 
'It is very significant that the African representatives were 
involved in the very conception of the EDCPT ini t iat ive/ 
adds Fred Binka, lecturer at Ghana University's School of 
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Public Health. 'This is a first as the other programmes we knew 
about were prepared without us and we were simply invited to 
participate. In the present case, we are bringing in our African 
knowledge and experience and have the assurance that the pro-
gramme will consider our real needs and expectations.' 
'In this context, one of the tasks during the project's prepara-
tory stage is to provide the necessary training in terms of good 
laboratory and clinical practices at every level of health policy 
implementation. The EDCTP can also be the means by which 
African specialists can find opportunities to use their skills in 
their own countries, therefore putting a brake on the brain 
drain which is robbing Africa of valuable skills,' concludes 
Antoni Trilla. O 
Ethics and 
clinical trials 
The Helsinki Declaration (1964), adopted by the World 
Medical Association, is the principal ethical code 
governing clinical trials on human beings. It lays 
down three major principles: the well-being of the sub-
ject must take precedence over the interests of science; 
subjects must give their consent freely and in full 
knowledge of the facts; and subjects must be assured of 
benefiting from the best treatment on conclusion of 
the trials. 
Although the first of these rules is clearly respected in 
the case of clinical research in southern countries, the 
matter of informing the populations in question and 
obtaining their consent must always be borne in mind 
in cultural contexts which are ill-prepared for this kind 
of approach. The third principle is currently the sub-
ject of debate. Many clinical trials carried out on Aids 
in developing countries during recent years related to 
treatments more likely to be applied in rich countries 
and beyond the reach of local socio-economic resources. 
The EDCTP should not stand accused of this as its goal 
is the development of treatment of direct use by these 
countries. 'But the time it takes before they become 
available and the way local health authorities make 
them available are also very important parameters 
when evaluating the ethical aspects linked to the 
carrying out of trials,' stresses Antoni Trilla. 'In any 
event, the criteria applied will be those habitually 
applied in developed countries, but the reality of the 
situation facing Africa must also be taken into account.' 
Malaria: decisive clinical trial 
in Mozambique 
At the beginning of July, under the direction of Dr Ricardo Thompson, special-
ist in research on malaria and director of public health, Mozambique carried out 
further clinical trials on a promising potential vaccine developed by Glaxo-
SmithKline (GSK). These phase I trials follow previous trials in Gambia and are 
intended to confirm the harmlessness of vaccines, established in Gambia, on a 
limited group of children. Once this is confirmed, the specialists will launch 
phase II to determine the likely initial treatment benefits of the tested molecule 
among a wider population. These trials are being carried out in partnership with 
the Malaria Vaccine Initiative network and the International Health Centre at 
the Hospital Clinic of Barcelona, under the direction of Dr Pedro Alonso. Nego-
tiations have also been initiated with the Bill and Melinda Gates foundation to 
reduce the production costs of treatment developed by GSK. 
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C h a r g e d b y t h e C o m m i s s i o n , t h e He ls ink i G r o u p has jus t p u b l i s h e d t h e resul ts o f a 
p a i n s t a k i n g task: a n e v a l u a t i o n of t h e s i t u a t i o n o f m e n a n d w o m e n sc ient is ts t h r o u g h o u t 
E u r o p e . It i n v o l v e d c o m p i l i n g c o m p a r a b l e s ta t is t ics as w e l l as o b s e r v i n g l e g i s l a t i o n a n d 
speci f ic i n i t i a t i v e s in o v e r 3 0 c o u n t r i e s d e s i g n e d t o c r e a t e a g e n d e r b a l a n c e . 
Equal skills for an 
equal career? 
In the EU, 70% of 
university researchers 
are men. Trailing 
the field are Belgium, 
the Netherlands and 
Germany, with under 
20% of women 
researchers. In Ireland, 
Greece and Portugal 
more than 40% 
of higher education 
teaching staff are 
women. 
© NeuroSearch 
' N o statistics, no p rob lem, no pol icy. Statistics help to identi fy 
problems and make it possible to measure the effectiveness of 
remedies, ' believes the British sociologist Hilary Rose. This is 
the task w h i c h the Commiss ion ent rus ted to the Helsinki 
Group on W o m e n and Science. (') The results are presented in 
the report ent i t led National Policies on Women and Science in 
Europe, published last June, which as wel l as a wealth of statis-
tics also sets out the principles of pol icy and good practices to 
p romote an increased role for w o m e n in science and research. 
The balance of the sexes 
'There is considerable diversity f rom one country to another in 
terms of scientific infrastructures and the cl imate permi t t ing 
w o m e n to pursue their career,' notes Teresa Rees, lecturer at 
Cardiff University's School of Social Sciences. 'But there are 
also c o m m o n factors, such as the lack of a balance between 
the sexes in more senior positions - at the level where scientific 
pol icy is decided. ' 
A number of at tempts are being made to correct this gender 
imba lance. The Commiss ion suppor ts a pol icy of ' gender 
mainst reaming' which involves taking the gender dimension 
systematically into account in all research programmes and 
policies. This approach is most in evidence in northern Europe. 
One example of this is the Equality Plan 2001-2003 imple-
mented by the Finnish Academy which states that, given equal 
skills, preference should be given to either men or w o m e n 
depending on which of the genders is less represented. In this 
very egalitarian country - wh ich has the highest standard of 
education in the wor ld - 5 8 % of university degrees and 4 5 % 
of doctorates were awarded to w o m e n in 2 0 0 1 . But just 2 0 % 
- an EU record low - of teaching staff in higher educat ion 
are w o m e n . 
This f igure is indicative of the remaining imbalance when it 
comes to exercising positions of responsibility in the scientific 
hierarchy (see graph). In Europe's universities as a whole, 8 9 % of 
those in the most senior posts are men. It is to remedy this situa-
t ion that the French Research Ministry set up the Mission pour la 
parité en sciences et en technologies, one of the principal objectives 
of which is to 'achieve a balance between the sexes on delibera-
tive and consultative bodies'. The order is to go out for women 
to make up one-third of staff in bodies on wh ich the public 
authori t ies are represented, compared w i t h 1 0 % at present. 
Setting the example 
European Research Commissioner Philippe Busquin believes that 
the absence of women in positions of responsibility 'is not of an 
emotional nature, but the manifestation of discrimination which 
is the result of several factors'. These factors include lack of inter-
est in science, the difficulty of returning to a job wi th the same sta-
tus after a career break, a traditional conf inement to certain tasks 
and a reluctance to accept certain posts which is more cultural 
than natural. This is why the Commission has decided to set the 
example by helping w o m e n to overcome this obstacle course. 
Under the Fifth Framework Programme, the target was for 4 0 % 
of the EU-funded Marie Cur ie research fe l lowships to be 
awarded to women - the figure was 38 .9% in 1999 and 37 .3% 
in 2000 - and for members of groups of experts appointed by 
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the Commission to include 4 0 % women, irrespective of 
f ield. The progress made was very real, women some-
times exceeding 5 0 % . The same desire to correct the 
imbalance was evident in the research projects submitted 
to the Commission in which the more active participation 
of women was explicitly desired. The result is that 1 8 % of 
women scientists were project coordinators under the 
Fifth Framework Programme compared w i th 1 0 % in the 
previous one. 
'Gender' research 
This strategy is progressively enabling women to increase 
their presence. The Sixth Framework Programme is simi-
larly commi t ted to correcting the gender balance and 
has in t roduced new measures to this end . Particular 
attent ion wil l be paid to compi l ing statistics on the par-
t icipation and role of w o m e n in European research and 
to gender studies. 
The lat ter have deve loped considerably over recent 
years, mainly in northern Europe. In Norway, for example, 
a section of the Research Counci l of Norway is mainly 
concerned w i t h analysing and p lanning a research pol -
icy to p romo te equal i ty between the sexes, based on 
exist ing nat ional and in ternat ional experiences. The 
Netherlands too has taken this quest ion very seriously 
since the 1980s. The Ne ther lands Associat ion for 
Women 's Studies publishes the Tijdschrift voor gender-
studies, special chairs have been created and a 'gender ' 
approach is app l ied systemat ical ly in f ields rang ing 
f rom l i terature to medic ine. O 
About 10% of research posts in engineering and technology 
are held by women. Relatively more women are active in 
agronomical science, where they account for 28% of 
researchers, as a European Union average. Most women 
researchers are active in the social and human sciences. 
There is also a high percentage of women in the medical 
sciences, with Ireland (72%) and Portugal (65%) leading 
the field. 
© CropDesign 
(1) Comprising civil servants and experts on gender issues from 
the Member States and associated countries, this group is charged 
with promoting debates and exchanges of experience on measures 
to promote the participation of women in research. 
Contact: 
Brigitte Degen -Women and Science Unit, Research DG 
Brigitte.Degen@cec.eu.int 
% 
T h e typical d e v e l o p m e n t o f a scientif ic career , per g e n d e r . 
This g r a p h of t h e s i tuat ion in Austr ia ( 1 9 9 8 ) is represen ta t i ve of all t h e E u r o p e a n countr ies: 
t h e h i g h e r u p t h e universi ty h ierarchy y o u c l imb , t h e f e w e r w o m e n y o u f i n d . 
To find out more 
Olhe Helsinki Group 
www.cordis.lu/improving/ 
women/helsinki.htm 
OStatistics and indicators 
http://europa.eu.int/comm/ 
research/sciencesociety/ 
women/wssi/index_en.html 
O'Gender and Research' 
information at European level 
www.cordis.lu/improving/ 
women/home.htm 
OReport of the Helsinki Group -
National policies on'women 
and science' 
www.cordis.lu/improving/ 
women/policies.htm 
www.cordis.lu/improving/ 
women/reports.htm 
Heysel Conference 
OA number of thematic workshops 
on women and research will be 
held during the Heysel Conference 
in Brussels from 11 to 13 November, 
on the occasion of the launch of 
the Sixth Framework Programme. 
http://europa.eu.int/comm/ 
research/conferences/ 
2002/index_en.html>Women 
Women and 
industrial research 
Olhe STRATA-ETAN high-level group 
of experts is currently studying 
the situation of researchers in 
the private sector. An international 
conference will be held on this 
subject in Berlin in the spring 
of 2003. 
http://europa.eu.int/comm/ 
research/sciencesociety/ 
women/wir/index_en.html 
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Introduction to the Sixth Framework Programme 
Participating in European research 
This 88-page guide provides useful back­
ground information, tips and a general 
overview of FP6 for potential project 
participants. 
FP6 instruments 
This brochure (16 pages) gives an 
introduction to the instruments, 
new and traditional, available for 
implementing the priority thematic 
areas of FP6. 
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The priorities of 
the Sixth Framework 
Programme 2002-2006 
RTD info: The priorities of the Sixth Framework Programme 2002-2006 
This special issue of RTD info magazine (32 pages) proposes a systematic overview of 
the seven thematic priorities of FP6: 
• Life sciences, genomics and biotechnology for health 
• Information society technologies 
• Nanotechnologies and nanosciences, knowledge-based multifunctional materials and 
new production processes and devices 
• Aeronautics and Space 
• Food quality and safety 
• Sustainable development, global change and ecosystems 
• Citizens and governance in a knowledge-based society. 
Another special issue of RTD info has been published recently on 
the opportunities for European research resulting from EU 
enlargement (Special Edition October 2002, 16 pages). 
All these publications can be obtained by sending a request to research@cec.eu.int 
